burstthepulp的个人主页 - 老虎社区

burstthepulp

burstthepulp

暂无个人介绍

IP属地：未知

5关注

2粉丝

0主题

0勋章

2021-08-18

Honestly in my humble opinion, with the strong and rapid spread of the delta variant, there's going to be an increase in demand for vaccine jabs and booster jabs - making $Moderna, Inc.(MRNA)$a very much keep-worthy stock vs. dumping it.

2021-11-19

about time! so many different studies have showed increased protection with $Moderna, Inc.(MRNA)$

Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older<blockquote>Moderna 宣布 FDA 批准在美国为 18 岁及以上成年人接种加强剂量的 COVID-19 疫苗</blockquote>

2021-12-09

to the moon! [Cool] [Cool]

Apple shares rose nearly 2% to a new high<blockquote>苹果股价上涨近2%创新高</blockquote>

2021-12-01

A good time to buy in $Sea Ltd(SE)$[Cool]

抱歉，原内容已删除

2021-11-26

To the moon! $Moderna, Inc.(MRNA)$[财迷] [财迷]

Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23%.<blockquote>疫苗股早盘继续上涨，Moderna股价飙升超过23%。</blockquote>

2021-12-09

very insightful article and shed some light on why $Grab Holdings(GRAB)$is doing so badly. only wish it came out earlier [Cry]

抱歉，原内容已删除

2021-12-09

wanted to buy the dip but there isn't really a dip with [LOL]

Amazon shares fell slightly by 0.5% in premarket trading<blockquote>亚马逊股价在盘前交易中小幅下跌 0.5%</blockquote>

2021-12-18

mmmm

Why Pfizer and Johnson & Johnson Fell on Friday<blockquote>为什么辉瑞和强生公司周五下跌</blockquote>

2021-11-29

[财迷]

Moderna stock surged 8% in premarket trading<blockquote>Moderna 股价在盘前交易中飙升 8%</blockquote>

2021-12-18

buy at dip? [Cool]

Amazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group<blockquote>印度暂停与 Future Group 2019 年的交易，亚马逊早盘下跌近 2%</blockquote>

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4089880892731870","uuid":"4089880892731870","gmtCreate":1626780217195,"gmtModify":1629265225755,"name":"burstthepulp","pinyin":"burstthepulp","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":5,"tweetSize":16,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.01.02","exceedPercentage":"80.50%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.07","exceedPercentage":"60.06%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":693612253,"gmtCreate":1640012711495,"gmtModify":1640012711612,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089880892731870","idStr":"4089880892731870"},"themes":[],"title":"","htmlText":"wonder why the shares isn't growing 37-fold&nbsp;[Smug]&nbsp;","listText":"wonder why the shares isn't growing 37-fold&nbsp;[Smug]&nbsp;","text":"wonder why the shares isn't growing 37-fold [Smug]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693612253","repostId":"2192318994","repostType":2,"isVote":1,"tweetType":1,"viewCount":3271,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693134149,"gmtCreate":1639983725886,"gmtModify":1639983734484,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089880892731870","idStr":"4089880892731870"},"themes":[],"title":"","htmlText":"Holding my breath as I await the climb&nbsp;[LOL]&nbsp;","listText":"Holding my breath as I await the climb&nbsp;[LOL]&nbsp;","text":"Holding my breath as I await the climb [LOL]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693134149","repostId":"1109541249","repostType":4,"repost":{"id":"1109541249","kind":"news","pubTimestamp":1639972523,"share":"https://www.laohunote.com/m/news/1109541249?lang=zh_CN&edition=full","pubTime":"2021-12-20 11:55","market":"us","language":"en","title":"Sea Stock: Down 43% From Its High, is a Buy Now?<blockquote>Sea股票：较高点下跌43%，现在买入吗？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1109541249","media":"Seeking Alpha","summary":"Summary\n\nSea Limited stock has been battered recently as growth stocks sold off massively in the mar","content":"<p><b>Summary</b></p><p><blockquote><b>总结</b></blockquote></p><p> <ul>  <li>Sea Limited stock has been battered recently as growth stocks sold off massively in the market.</li>  <li>However, we believe that the fundamental thesis on its rapid growth remains robust.</li>  <li>We discuss why investors should capitalize on its recent significant correction to add exposure.</li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/aa5cbe0a30acc723a2c6f62300024002\" tg-width=\"1536\" tg-height=\"1024\" referrerpolicy=\"no-referrer\"><span>kokkai/iStock Unreleased via Getty Images</span></p><p><blockquote><ul><li>由于市场成长型股票大幅抛售，Sea Limited 的股票最近遭受重创。</li><li>然而，我们认为其快速增长的基本论点仍然稳固。</li><li>我们讨论为什么投资者应该利用最近的重大调整来增加风险敞口。</li></ul><p class=\"t-img-caption\"><span>kokkai/iStock 未通过 Getty Images 发布</span></p></blockquote></p><p> <b>Investment Thesis</b></p><p><blockquote><b>投资论文</b></blockquote></p><p> Sea Limited(NYSE:SE)&nbsp;stock is one of our highest conviction growth stocks that has been severely battered over the last month. Since its recent all-time high (ATH) in October, its price has dropped by a dramatic 43%. Many reasons have been presented on why the stock has fallen. We exhort investors not to read too much into them. We believe nothing material has changed from its fundamental thesis. The stock has had a remarkable run in 2021 relative to its gaming peers or e-tailer peers. Therefore, profit-taking of this extent should not be surprising as fear struck growth stocks.</p><p><blockquote>Sea Limited（纽约证券交易所股票代码：SE）股票是我们最相信的成长型股票之一，在上个月遭受了严重打击。自 10 月份创下历史新高 (ATH) 以来，其价格已大幅下跌 43%。关于该股下跌的原因有很多。我们建议投资者不要过多地解读它们。我们认为它的基本论点没有任何实质性的改变。相对于游戏同行或电子零售商同行，该股在 2021 年表现出色。因此，当恐惧袭击成长型股票时，这种程度的获利了结并不奇怪。</blockquote></p><p> Moreover, the recent significant correction in growth stocks across the market has also hit SE stock hard. But, we are not concerned. Significant volatility will always be a factor influencing the performance of growth stocks like SE in the short term.</p><p><blockquote>此外，近期全市场成长股的大幅回调也对SE股造成了沉重打击。但是，我们并不担心。短期内，显著的波动性始终是影响SE等成长股表现的一个因素。</blockquote></p><p> Notably, we observed that the consensus target price on SE stock had been revised upwards since its FQ3 report card. Moreover, the gap between its price target and its current stock price has been greater than its last significant correction in April/May.</p><p><blockquote>值得注意的是，我们观察到，自第三季度报告以来，SE 股票的一致目标价已被上调。此外，其目标价与其当前股价之间的差距已经大于其上一次在4月/5月的大幅调整。</blockquote></p><p> Our internal DCF valuation model also points to a stock that is now significantly undervalued. Thanks to the market's myopia, we have been presented with another fantastic opportunity since April/May to add SE stock with great fervor again.</p><p><blockquote>我们的内部 DCF 估值模型还指出了一只目前被严重低估的股票。由于市场的短视，自4月/5月以来，我们又迎来了一个绝佳的机会，再次以极大的热情增持SE股票。</blockquote></p><p> We discuss why we think investors should not miss this incredible opportunity to add exposure to an outstanding growth stock.</p><p><blockquote>我们讨论为什么我们认为投资者不应该错过这个难以置信的机会来增加对优秀成长型股票的投资。</blockquote></p><p> <b>SE Stock YTD Performance</b></p><p><blockquote><b>SE 股票年初至今表现</b></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6c191d1f0f6a10e392845cdbda1264aa\" tg-width=\"640\" tg-height=\"331\" referrerpolicy=\"no-referrer\"><span>SE stock YTD performance (as of 17 December'21).</span></p><p><blockquote><p class=\"t-img-caption\"><span>SE股票年初至今表现（截至21年12月17日）。</span></p></blockquote></p><p> As a result of the significant correction recently, SE stock's YTD return has dropped to 6.9%, thus underperforming the market. Notably, its YTD gain was as high as 80% in October/early November. Despite that, the stock is still outperforming its e-tailer and gaming peers, as shown above.</p><p><blockquote>由于最近的大幅调整，SE股票的年初至今回报率已降至6.9%，因此跑输大盘。值得注意的是，其年初至今的涨幅在10月/11月初高达80%。尽管如此，如上图所示，该股的表现仍然优于电子零售商和游戏同行。</blockquote></p><p> <b>Sea Stock Estimates Have Consistently Been Revised Upwards</b></p><p><blockquote><b>Sea 股票预测一直被上调</b></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8555128e2a30e924dd6c2dd162a27eea\" tg-width=\"640\" tg-height=\"396\" referrerpolicy=\"no-referrer\"><span>Sea Limited revised revenue mean consensus estimates. Data source: S&amp;P Capital IQ, Seeking Alpha</span></p><p><blockquote><p class=\"t-img-caption\"><span>Sea Limited 修订后的收入平均共识估计。数据来源：标普资本智商、Seeking Alpha</span></p></blockquote></p><p> Readers can quickly observe that the company's revenue consensus estimates for FY21-23 have consistently been revised upwards over the last five months. These revisions lend credence to the robust growth prospects of the company over the next two years. Notably, Sea Limited's revenue is estimated to increase at a phenomenal CAGR of 42.8% through FY23.</p><p><blockquote>读者可以很快观察到，该公司对 21-23 财年的收入共识预期在过去五个月中一直被上调。这些修订为公司未来两年强劲的增长前景提供了可信度。值得注意的是，Sea Limited 的收入预计将通过2023财年以 42.8% 的惊人复合年增长率增长。</blockquote></p><p> There were concerns over the growth rates of its Garena gaming arm in its FQ3 report card.We also explained in our previous article&nbsp;that Sea Limited has clearly explained that investors should expect normalization in Garena's growth after two spectacular years. However, its monetization capability continues to dazzle. Therefore, we are confident that Garena can continue its robust monetization strategies moving forward.</p><p><blockquote>第三季度成绩单中对 Garena 游戏部门的增长率表示担忧。我们还在之前的文章中解释说，Sea Limited 已明确解释说，投资者应该期待 Garena 在经历了辉煌的两年后增长恢复正常。然而，其变现能力继续令人眼花缭乱。因此，我们相信 Garena 能够继续其稳健的货币化战略。</blockquote></p><p> Moreover, data from Sensor Tower's recent gaming statistics continue to point to sturdy performance from its Free Fire game. It continues to be ranked among the&nbsp;top ten mobile games in terms of overall gaming revenue&nbsp;in November. Moreover, it's also ranked#2 in overall downloadsacross both the App Store and Google Play. Notably, it's also among&nbsp;eight games globally whose annual revenue crossed $1B&nbsp;as of 14 December. Therefore, we think the sentiments and chatter about Free Fire's \"one-shot wonder\" have been overblown.</p><p><blockquote>此外，Sensor Tower最近的游戏统计数据继续表明其Free Fire游戏的强劲表现。就11月游戏整体收入而言，它继续位居移动游戏前十。此外，它在App Store和Google Play的总下载量中也排名第二。值得注意的是，截至12月14日，它也是全球八款年收入超过10亿美元的游戏之一。因此，我们认为关于Free Fire“一次性奇迹”的情绪和喋喋不休被夸大了。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/51247ba1efd7fa6d333b482446e94c9a\" tg-width=\"515\" tg-height=\"380\" referrerpolicy=\"no-referrer\"><span>Global games market forecast. Source: Google, Newzoo</span></p><p><blockquote><p class=\"t-img-caption\"><span>全球游戏市场预测。资料来源：谷歌、Newzoo</span></p></blockquote></p><p></p><p> In addition, the global gaming market is estimated to experience a slight decline to $175.8B after last year's massive 23% growth to $177.8B. However, given Garena's impressive growth in FY21 despite the decline in the global market, we believe it validates its business model and prospects. Notably, the gaming market is expected to reverse its decline moving forward. Therefore, Garena's leadership in mobile gaming could continue to propel its growth underpinned by the recovery in the global gaming market.</p><p><blockquote>此外，全球博彩市场在去年大幅增长 23% 至 177.8B 美元后，预计将略有下降至 175.8B 美元。然而，鉴于尽管全球市场下滑，Garena 在 2021 财年仍实现了令人印象深刻的增长，我们相信这验证了其商业模式和前景。值得注意的是，博彩市场有望在未来扭转颓势。因此，在全球游戏市场复苏的推动下，Garena 在移动游戏领域的领导地位可能会继续推动其增长。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0a0612da9a19f7b7198d43213b4f4470\" tg-width=\"640\" tg-height=\"396\" referrerpolicy=\"no-referrer\"><span>Shopee adjusted EBITDA per order. Data source: Company filings</span></p><p><blockquote><p class=\"t-img-caption\"><span>Shopee 调整了每个订单的 EBITDA。数据来源：公司文件</span></p></blockquote></p><p> But, some investors may have been spooked by Shopee's (Sea Limited's e-commerce arm) continued expansion into new geographical markets. Notably, Shopee continues to report adjusted EBITDA loss per order, as shown above. Therefore, some investors might have been concerned about whether the company's plate is getting too much to handle. Over the last three months, the company has entered into new markets such as India, France, Spain, and Poland. They are in addition to its battle with MercadoLibre (MELI) in Latin America, particularly Brazil. As a result, there are concerns on whether Sea Limited could continue its adroit execution in these markets while still making losses. We believe such concerns are valid. However, Sea Limited has shown its tremendous capability in penetrating the most important markets where the incumbents have strong leadership. It includes Lazada (BABA) in Southeast Asia, MercadoLibre in Brazil, and Tokopedia in Indonesia. Shopee was never the first-mover. But, it took advantage as the \"late-comer\" as it sought to compete with the incumbents. It's important to note that Sea Limited is not averse to competition. It has thrived against the incumbents and has made the e-commerce space in these geographical regions much more competitive.</p><p><blockquote>但是，一些投资者可能对 Shopee（Sea Limited 的电子商务部门）向新地理市场的持续扩张感到害怕。值得注意的是，Shopee 继续报告每个订单的调整后 EBITDA 损失，如上所示。因此，一些投资者可能担心该公司的盘子是否有太多难以处理。在过去的三个月里，该公司进入了印度、法国、西班牙和波兰等新市场。此外，它还在拉丁美洲，特别是巴西与自由市场（MELI）的斗争。因此，人们担心 Sea Limited 能否在这些市场继续其娴熟的执行，同时仍在亏损。我们认为这种担忧是合理的。然而，Sea Limited 在渗透现有企业拥有强大领导地位的最重要市场方面表现出了巨大的能力。它包括东南亚的Lazada（BABA）、巴西的MercadoLibre和印度尼西亚的Tokopedia。Shopee从来都不是先行者。但是，它利用了“后来者”的优势，试图与现任者竞争。值得注意的是，Sea Limited并不反对竞争。它与现有企业相比蓬勃发展，并使这些地理区域的电子商务领域更具竞争力。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/80938433e2d55307ca40000eeea2a26f\" tg-width=\"640\" tg-height=\"396\" referrerpolicy=\"no-referrer\"><span>Sea Limited revised adjusted EPS mean consensus estimates. Data source: S&amp;P Capital IQ, Seeking Alpha</span></p><p><blockquote><p class=\"t-img-caption\"><span>Sea Limited 修订调整后每股收益平均共识估计。数据来源：标普资本智商、Seeking Alpha</span></p></blockquote></p><p> Nevertheless, the road towards profitability might be stretched further due to its e-commerce expansion. Readers can quickly glance over the chart above, where its adjusted EPS estimates have been revised downwards through FY23 over the last five months. However, we believe that if you are a long-term investor with a five-year horizon at least, it's not a cause for concern. Earlier investors in Sea Limited can keenly recall the company's massive adjusted EBITDA per order losses, as seen in the previous chart. Shopee has scaled tremendously over the last five years and has improved its operating leverage further. But, it's important to note that it takes time to scale up. Therefore, earlier losses in new geographical markets are expected. But, management has demonstrated its execution capability over the last three years. Considering its much reduced adjusted EBITDA losses over the previous few years, we believe that Shopee is even better positioned than before to navigate its expansion.</p><p><blockquote>然而，由于其电子商务的扩张，盈利之路可能会进一步延长。读者可以快速浏览上图，其中2023财年在过去五个月中对其调整后的每股收益预期进行了下调。然而，我们认为，如果您是至少有五年期限的长期投资者，则无需担心。Sea Limited 的早期投资者可以清楚地回忆起该公司每笔订单的巨额调整后 EBITDA 损失，如上图表所示。Shopee 在过去五年中规模巨大，并进一步提高了运营杠杆。但是，重要的是要注意，扩大规模需要时间。因此，预计新地理市场的早期亏损。但是，管理层在过去三年中已经展示了其执行能力。考虑到过去几年调整后 EBITDA 亏损大幅减少，我们相信 Shopee 比以前更有能力进行扩张。</blockquote></p><p> <b>So, is SE Stock a Buy Now?</b></p><p><blockquote><b>那么，SE 股票现在值得买入吗？</b></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3dbc835e49ded8a7a0e5f4fcc9e10649\" tg-width=\"640\" tg-height=\"384\" referrerpolicy=\"no-referrer\"><span>SE stock EV/NTM Revenue 4Y mean.</span></p><p><blockquote><p class=\"t-img-caption\"><span>SE股票EV/NTM收入4年平均值。</span></p></blockquote></p><p> SE stock is trading at an EV/NTM Revenue of 8.3x. Therefore, it has brought it back to its 4Y NTM revenue multiple mean of 8.6x. We believe there's a fantastic opportunity right now as the market has undoubtedly overreacted. As demonstrated clearly, SE is still expected to generate massive revenue growth moving ahead, even though it means the road to profitability gets further extended.</p><p><blockquote>SE 股票的 EV/NTM 收入为 8.3 倍。因此，它已将其恢复到 4 年 NTM 收入倍数平均值 8.6 倍。我们相信现在有一个绝佳的机会，因为市场无疑已经反应过度。正如清楚地表明的那样，SE 仍有望在未来实现巨大的收入增长，尽管这意味着盈利之路将进一步延长。</blockquote></p><p> Considering its FY23 revenue estimate, SE stock is trading at just 5.8x FY23 revenue. No one can accurately predict where the stock will be headed over the next few months. But, we think it represents a tremendous opportunity right now.</p><p><blockquote>考虑到其2023财年收入预期，SE 股票的交易价格仅为2023财年收入的 5.8 倍。没有人能够准确预测该股未来几个月的走势。但是，我们认为现在这是一个巨大的机会。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3bea18a0bdfd970ea640308dc35e099c\" tg-width=\"635\" tg-height=\"362\" referrerpolicy=\"no-referrer\"><span>SE stock price target Vs. actual price trend. Source: Seeking Alpha</span></p><p><blockquote><p class=\"t-img-caption\"><span>SE 股价目标与实际价格趋势。来源：Seeking Alpha</span></p></blockquote></p><p></p><p> Moreover, readers can observe that the valuation gap between SE stock's consensus price target (PT) of $405.87 and its current price has never been more significant in a while. It's even more pronounced than its last significant correction in April/May. Notably, the consensus price target has been revised upwards despite the so-called \"gaming headwinds.\" And, if you look at the price chart, SE stock price has followed the revised PT trend very consistently over time. Therefore, the current price could be one of the most significant discounts you could observe in a long time.</p><p><blockquote>此外，读者可以观察到，SE 股票的共识目标价 (PT) 405.87 美元与其当前价格之间的估值差距一段时间以来从未如此显着。这比4月/5月的上一次大幅调整更加明显。值得注意的是，尽管存在所谓的“博彩逆风”，但共识目标价格已被上调。而且，如果你看一下价格图表，随着时间的推移，SE 股价一直非常一致地遵循修订后的 PT 趋势。因此，当前价格可能是您在很长一段时间内观察到的最大折扣之一。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/939a544ab94c9e2a2b8a6db943703b39\" tg-width=\"910\" tg-height=\"602\" referrerpolicy=\"no-referrer\"><span>SE stock DCF valuation model. Data source: S&amp;P Capital IQ, company filings, author</span></p><p><blockquote><p class=\"t-img-caption\"><span>SE股票DCF估值模型。数据来源：S&amp;P Capital IQ、公司文件、作者</span></p></blockquote></p><p> Our DCF model also shows that SE stock is now significantly undervalued with an implied fair value of $371.46. We have also used reasonable estimates in our model. Moreover, we believe that SE will continue to gain significant operating leverage as it scales in the new markets. We estimate that its adjusted EBITDA margins could reach 15% by FY25.</p><p><blockquote>我们的 DCF 模型还显示，SE 股票目前被严重低估，隐含公允价值为 371.46 美元。我们在模型中也使用了合理的估计。此外，我们相信，随着SE在新市场的扩大规模，SE将继续获得显著的运营杠杆。我们预计，到 2025 财年，其调整后 EBITDA 利润率可能达到 15%。</blockquote></p><p> Lastly, the stock is also testing a critical support level that has strongly underpinned the stock's advance since early 2021. Therefore, there are sufficient reasons to believe that the current entry point to add exposure to SE stock seems very attractive now.</p><p><blockquote>最后，该股还在测试一个关键支撑位，该支撑位自 2021 年初以来一直有力地支撑着该股的上涨。因此，有足够的理由相信，目前增加SE股票敞口的切入点现在看来非常有吸引力。</blockquote></p><p> Consequently,<i>we revise our rating on SE stock to Strong Buy</i>.</p><p><blockquote>因此，<i>我们将 SE 股票评级修改为强力买入</i>.</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sea Stock: Down 43% From Its High, is a Buy Now?<blockquote>Sea股票：较高点下跌43%，现在买入吗？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSea Stock: Down 43% From Its High, is a Buy Now?<blockquote>Sea股票：较高点下跌43%，现在买入吗？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-12-20 11:55</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b>Summary</b></p><p><blockquote><b>总结</b></blockquote></p><p> <ul>  <li>Sea Limited stock has been battered recently as growth stocks sold off massively in the market.</li>  <li>However, we believe that the fundamental thesis on its rapid growth remains robust.</li>  <li>We discuss why investors should capitalize on its recent significant correction to add exposure.</li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/aa5cbe0a30acc723a2c6f62300024002\" tg-width=\"1536\" tg-height=\"1024\" referrerpolicy=\"no-referrer\"><span>kokkai/iStock Unreleased via Getty Images</span></p><p><blockquote><ul><li>由于市场成长型股票大幅抛售，Sea Limited 的股票最近遭受重创。</li><li>然而，我们认为其快速增长的基本论点仍然稳固。</li><li>我们讨论为什么投资者应该利用最近的重大调整来增加风险敞口。</li></ul><p class=\"t-img-caption\"><span>kokkai/iStock 未通过 Getty Images 发布</span></p></blockquote></p><p> <b>Investment Thesis</b></p><p><blockquote><b>投资论文</b></blockquote></p><p> Sea Limited(NYSE:SE)&nbsp;stock is one of our highest conviction growth stocks that has been severely battered over the last month. Since its recent all-time high (ATH) in October, its price has dropped by a dramatic 43%. Many reasons have been presented on why the stock has fallen. We exhort investors not to read too much into them. We believe nothing material has changed from its fundamental thesis. The stock has had a remarkable run in 2021 relative to its gaming peers or e-tailer peers. Therefore, profit-taking of this extent should not be surprising as fear struck growth stocks.</p><p><blockquote>Sea Limited（纽约证券交易所股票代码：SE）股票是我们最相信的成长型股票之一，在上个月遭受了严重打击。自 10 月份创下历史新高 (ATH) 以来，其价格已大幅下跌 43%。关于该股下跌的原因有很多。我们建议投资者不要过多地解读它们。我们认为它的基本论点没有任何实质性的改变。相对于游戏同行或电子零售商同行，该股在 2021 年表现出色。因此，当恐惧袭击成长型股票时，这种程度的获利了结并不奇怪。</blockquote></p><p> Moreover, the recent significant correction in growth stocks across the market has also hit SE stock hard. But, we are not concerned. Significant volatility will always be a factor influencing the performance of growth stocks like SE in the short term.</p><p><blockquote>此外，近期全市场成长股的大幅回调也对SE股造成了沉重打击。但是，我们并不担心。短期内，显著的波动性始终是影响SE等成长股表现的一个因素。</blockquote></p><p> Notably, we observed that the consensus target price on SE stock had been revised upwards since its FQ3 report card. Moreover, the gap between its price target and its current stock price has been greater than its last significant correction in April/May.</p><p><blockquote>值得注意的是，我们观察到，自第三季度报告以来，SE 股票的一致目标价已被上调。此外，其目标价与其当前股价之间的差距已经大于其上一次在4月/5月的大幅调整。</blockquote></p><p> Our internal DCF valuation model also points to a stock that is now significantly undervalued. Thanks to the market's myopia, we have been presented with another fantastic opportunity since April/May to add SE stock with great fervor again.</p><p><blockquote>我们的内部 DCF 估值模型还指出了一只目前被严重低估的股票。由于市场的短视，自4月/5月以来，我们又迎来了一个绝佳的机会，再次以极大的热情增持SE股票。</blockquote></p><p> We discuss why we think investors should not miss this incredible opportunity to add exposure to an outstanding growth stock.</p><p><blockquote>我们讨论为什么我们认为投资者不应该错过这个难以置信的机会来增加对优秀成长型股票的投资。</blockquote></p><p> <b>SE Stock YTD Performance</b></p><p><blockquote><b>SE 股票年初至今表现</b></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6c191d1f0f6a10e392845cdbda1264aa\" tg-width=\"640\" tg-height=\"331\" referrerpolicy=\"no-referrer\"><span>SE stock YTD performance (as of 17 December'21).</span></p><p><blockquote><p class=\"t-img-caption\"><span>SE股票年初至今表现（截至21年12月17日）。</span></p></blockquote></p><p> As a result of the significant correction recently, SE stock's YTD return has dropped to 6.9%, thus underperforming the market. Notably, its YTD gain was as high as 80% in October/early November. Despite that, the stock is still outperforming its e-tailer and gaming peers, as shown above.</p><p><blockquote>由于最近的大幅调整，SE股票的年初至今回报率已降至6.9%，因此跑输大盘。值得注意的是，其年初至今的涨幅在10月/11月初高达80%。尽管如此，如上图所示，该股的表现仍然优于电子零售商和游戏同行。</blockquote></p><p> <b>Sea Stock Estimates Have Consistently Been Revised Upwards</b></p><p><blockquote><b>Sea 股票预测一直被上调</b></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8555128e2a30e924dd6c2dd162a27eea\" tg-width=\"640\" tg-height=\"396\" referrerpolicy=\"no-referrer\"><span>Sea Limited revised revenue mean consensus estimates. Data source: S&amp;P Capital IQ, Seeking Alpha</span></p><p><blockquote><p class=\"t-img-caption\"><span>Sea Limited 修订后的收入平均共识估计。数据来源：标普资本智商、Seeking Alpha</span></p></blockquote></p><p> Readers can quickly observe that the company's revenue consensus estimates for FY21-23 have consistently been revised upwards over the last five months. These revisions lend credence to the robust growth prospects of the company over the next two years. Notably, Sea Limited's revenue is estimated to increase at a phenomenal CAGR of 42.8% through FY23.</p><p><blockquote>读者可以很快观察到，该公司对 21-23 财年的收入共识预期在过去五个月中一直被上调。这些修订为公司未来两年强劲的增长前景提供了可信度。值得注意的是，Sea Limited 的收入预计将通过2023财年以 42.8% 的惊人复合年增长率增长。</blockquote></p><p> There were concerns over the growth rates of its Garena gaming arm in its FQ3 report card.We also explained in our previous article&nbsp;that Sea Limited has clearly explained that investors should expect normalization in Garena's growth after two spectacular years. However, its monetization capability continues to dazzle. Therefore, we are confident that Garena can continue its robust monetization strategies moving forward.</p><p><blockquote>第三季度成绩单中对 Garena 游戏部门的增长率表示担忧。我们还在之前的文章中解释说，Sea Limited 已明确解释说，投资者应该期待 Garena 在经历了辉煌的两年后增长恢复正常。然而，其变现能力继续令人眼花缭乱。因此，我们相信 Garena 能够继续其稳健的货币化战略。</blockquote></p><p> Moreover, data from Sensor Tower's recent gaming statistics continue to point to sturdy performance from its Free Fire game. It continues to be ranked among the&nbsp;top ten mobile games in terms of overall gaming revenue&nbsp;in November. Moreover, it's also ranked#2 in overall downloadsacross both the App Store and Google Play. Notably, it's also among&nbsp;eight games globally whose annual revenue crossed $1B&nbsp;as of 14 December. Therefore, we think the sentiments and chatter about Free Fire's \"one-shot wonder\" have been overblown.</p><p><blockquote>此外，Sensor Tower最近的游戏统计数据继续表明其Free Fire游戏的强劲表现。就11月游戏整体收入而言，它继续位居移动游戏前十。此外，它在App Store和Google Play的总下载量中也排名第二。值得注意的是，截至12月14日，它也是全球八款年收入超过10亿美元的游戏之一。因此，我们认为关于Free Fire“一次性奇迹”的情绪和喋喋不休被夸大了。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/51247ba1efd7fa6d333b482446e94c9a\" tg-width=\"515\" tg-height=\"380\" referrerpolicy=\"no-referrer\"><span>Global games market forecast. Source: Google, Newzoo</span></p><p><blockquote><p class=\"t-img-caption\"><span>全球游戏市场预测。资料来源：谷歌、Newzoo</span></p></blockquote></p><p></p><p> In addition, the global gaming market is estimated to experience a slight decline to $175.8B after last year's massive 23% growth to $177.8B. However, given Garena's impressive growth in FY21 despite the decline in the global market, we believe it validates its business model and prospects. Notably, the gaming market is expected to reverse its decline moving forward. Therefore, Garena's leadership in mobile gaming could continue to propel its growth underpinned by the recovery in the global gaming market.</p><p><blockquote>此外，全球博彩市场在去年大幅增长 23% 至 177.8B 美元后，预计将略有下降至 175.8B 美元。然而，鉴于尽管全球市场下滑，Garena 在 2021 财年仍实现了令人印象深刻的增长，我们相信这验证了其商业模式和前景。值得注意的是，博彩市场有望在未来扭转颓势。因此，在全球游戏市场复苏的推动下，Garena 在移动游戏领域的领导地位可能会继续推动其增长。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0a0612da9a19f7b7198d43213b4f4470\" tg-width=\"640\" tg-height=\"396\" referrerpolicy=\"no-referrer\"><span>Shopee adjusted EBITDA per order. Data source: Company filings</span></p><p><blockquote><p class=\"t-img-caption\"><span>Shopee 调整了每个订单的 EBITDA。数据来源：公司文件</span></p></blockquote></p><p> But, some investors may have been spooked by Shopee's (Sea Limited's e-commerce arm) continued expansion into new geographical markets. Notably, Shopee continues to report adjusted EBITDA loss per order, as shown above. Therefore, some investors might have been concerned about whether the company's plate is getting too much to handle. Over the last three months, the company has entered into new markets such as India, France, Spain, and Poland. They are in addition to its battle with MercadoLibre (MELI) in Latin America, particularly Brazil. As a result, there are concerns on whether Sea Limited could continue its adroit execution in these markets while still making losses. We believe such concerns are valid. However, Sea Limited has shown its tremendous capability in penetrating the most important markets where the incumbents have strong leadership. It includes Lazada (BABA) in Southeast Asia, MercadoLibre in Brazil, and Tokopedia in Indonesia. Shopee was never the first-mover. But, it took advantage as the \"late-comer\" as it sought to compete with the incumbents. It's important to note that Sea Limited is not averse to competition. It has thrived against the incumbents and has made the e-commerce space in these geographical regions much more competitive.</p><p><blockquote>但是，一些投资者可能对 Shopee（Sea Limited 的电子商务部门）向新地理市场的持续扩张感到害怕。值得注意的是，Shopee 继续报告每个订单的调整后 EBITDA 损失，如上所示。因此，一些投资者可能担心该公司的盘子是否有太多难以处理。在过去的三个月里，该公司进入了印度、法国、西班牙和波兰等新市场。此外，它还在拉丁美洲，特别是巴西与自由市场（MELI）的斗争。因此，人们担心 Sea Limited 能否在这些市场继续其娴熟的执行，同时仍在亏损。我们认为这种担忧是合理的。然而，Sea Limited 在渗透现有企业拥有强大领导地位的最重要市场方面表现出了巨大的能力。它包括东南亚的Lazada（BABA）、巴西的MercadoLibre和印度尼西亚的Tokopedia。Shopee从来都不是先行者。但是，它利用了“后来者”的优势，试图与现任者竞争。值得注意的是，Sea Limited并不反对竞争。它与现有企业相比蓬勃发展，并使这些地理区域的电子商务领域更具竞争力。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/80938433e2d55307ca40000eeea2a26f\" tg-width=\"640\" tg-height=\"396\" referrerpolicy=\"no-referrer\"><span>Sea Limited revised adjusted EPS mean consensus estimates. Data source: S&amp;P Capital IQ, Seeking Alpha</span></p><p><blockquote><p class=\"t-img-caption\"><span>Sea Limited 修订调整后每股收益平均共识估计。数据来源：标普资本智商、Seeking Alpha</span></p></blockquote></p><p> Nevertheless, the road towards profitability might be stretched further due to its e-commerce expansion. Readers can quickly glance over the chart above, where its adjusted EPS estimates have been revised downwards through FY23 over the last five months. However, we believe that if you are a long-term investor with a five-year horizon at least, it's not a cause for concern. Earlier investors in Sea Limited can keenly recall the company's massive adjusted EBITDA per order losses, as seen in the previous chart. Shopee has scaled tremendously over the last five years and has improved its operating leverage further. But, it's important to note that it takes time to scale up. Therefore, earlier losses in new geographical markets are expected. But, management has demonstrated its execution capability over the last three years. Considering its much reduced adjusted EBITDA losses over the previous few years, we believe that Shopee is even better positioned than before to navigate its expansion.</p><p><blockquote>然而，由于其电子商务的扩张，盈利之路可能会进一步延长。读者可以快速浏览上图，其中2023财年在过去五个月中对其调整后的每股收益预期进行了下调。然而，我们认为，如果您是至少有五年期限的长期投资者，则无需担心。Sea Limited 的早期投资者可以清楚地回忆起该公司每笔订单的巨额调整后 EBITDA 损失，如上图表所示。Shopee 在过去五年中规模巨大，并进一步提高了运营杠杆。但是，重要的是要注意，扩大规模需要时间。因此，预计新地理市场的早期亏损。但是，管理层在过去三年中已经展示了其执行能力。考虑到过去几年调整后 EBITDA 亏损大幅减少，我们相信 Shopee 比以前更有能力进行扩张。</blockquote></p><p> <b>So, is SE Stock a Buy Now?</b></p><p><blockquote><b>那么，SE 股票现在值得买入吗？</b></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3dbc835e49ded8a7a0e5f4fcc9e10649\" tg-width=\"640\" tg-height=\"384\" referrerpolicy=\"no-referrer\"><span>SE stock EV/NTM Revenue 4Y mean.</span></p><p><blockquote><p class=\"t-img-caption\"><span>SE股票EV/NTM收入4年平均值。</span></p></blockquote></p><p> SE stock is trading at an EV/NTM Revenue of 8.3x. Therefore, it has brought it back to its 4Y NTM revenue multiple mean of 8.6x. We believe there's a fantastic opportunity right now as the market has undoubtedly overreacted. As demonstrated clearly, SE is still expected to generate massive revenue growth moving ahead, even though it means the road to profitability gets further extended.</p><p><blockquote>SE 股票的 EV/NTM 收入为 8.3 倍。因此，它已将其恢复到 4 年 NTM 收入倍数平均值 8.6 倍。我们相信现在有一个绝佳的机会，因为市场无疑已经反应过度。正如清楚地表明的那样，SE 仍有望在未来实现巨大的收入增长，尽管这意味着盈利之路将进一步延长。</blockquote></p><p> Considering its FY23 revenue estimate, SE stock is trading at just 5.8x FY23 revenue. No one can accurately predict where the stock will be headed over the next few months. But, we think it represents a tremendous opportunity right now.</p><p><blockquote>考虑到其2023财年收入预期，SE 股票的交易价格仅为2023财年收入的 5.8 倍。没有人能够准确预测该股未来几个月的走势。但是，我们认为现在这是一个巨大的机会。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3bea18a0bdfd970ea640308dc35e099c\" tg-width=\"635\" tg-height=\"362\" referrerpolicy=\"no-referrer\"><span>SE stock price target Vs. actual price trend. Source: Seeking Alpha</span></p><p><blockquote><p class=\"t-img-caption\"><span>SE 股价目标与实际价格趋势。来源：Seeking Alpha</span></p></blockquote></p><p></p><p> Moreover, readers can observe that the valuation gap between SE stock's consensus price target (PT) of $405.87 and its current price has never been more significant in a while. It's even more pronounced than its last significant correction in April/May. Notably, the consensus price target has been revised upwards despite the so-called \"gaming headwinds.\" And, if you look at the price chart, SE stock price has followed the revised PT trend very consistently over time. Therefore, the current price could be one of the most significant discounts you could observe in a long time.</p><p><blockquote>此外，读者可以观察到，SE 股票的共识目标价 (PT) 405.87 美元与其当前价格之间的估值差距一段时间以来从未如此显着。这比4月/5月的上一次大幅调整更加明显。值得注意的是，尽管存在所谓的“博彩逆风”，但共识目标价格已被上调。而且，如果你看一下价格图表，随着时间的推移，SE 股价一直非常一致地遵循修订后的 PT 趋势。因此，当前价格可能是您在很长一段时间内观察到的最大折扣之一。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/939a544ab94c9e2a2b8a6db943703b39\" tg-width=\"910\" tg-height=\"602\" referrerpolicy=\"no-referrer\"><span>SE stock DCF valuation model. Data source: S&amp;P Capital IQ, company filings, author</span></p><p><blockquote><p class=\"t-img-caption\"><span>SE股票DCF估值模型。数据来源：S&amp;P Capital IQ、公司文件、作者</span></p></blockquote></p><p> Our DCF model also shows that SE stock is now significantly undervalued with an implied fair value of $371.46. We have also used reasonable estimates in our model. Moreover, we believe that SE will continue to gain significant operating leverage as it scales in the new markets. We estimate that its adjusted EBITDA margins could reach 15% by FY25.</p><p><blockquote>我们的 DCF 模型还显示，SE 股票目前被严重低估，隐含公允价值为 371.46 美元。我们在模型中也使用了合理的估计。此外，我们相信，随着SE在新市场的扩大规模，SE将继续获得显著的运营杠杆。我们预计，到 2025 财年，其调整后 EBITDA 利润率可能达到 15%。</blockquote></p><p> Lastly, the stock is also testing a critical support level that has strongly underpinned the stock's advance since early 2021. Therefore, there are sufficient reasons to believe that the current entry point to add exposure to SE stock seems very attractive now.</p><p><blockquote>最后，该股还在测试一个关键支撑位，该支撑位自 2021 年初以来一直有力地支撑着该股的上涨。因此，有足够的理由相信，目前增加SE股票敞口的切入点现在看来非常有吸引力。</blockquote></p><p> Consequently,<i>we revise our rating on SE stock to Strong Buy</i>.</p><p><blockquote>因此，<i>我们将 SE 股票评级修改为强力买入</i>.</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/article/4475931-sea-se-down-significantly-stock-strong-buy\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SE":"Sea Ltd"},"source_url":"https://seekingalpha.com/article/4475931-sea-se-down-significantly-stock-strong-buy","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109541249","content_text":"Summary\n\nSea Limited stock has been battered recently as growth stocks sold off massively in the market.\nHowever, we believe that the fundamental thesis on its rapid growth remains robust.\nWe discuss why investors should capitalize on its recent significant correction to add exposure.\n\nkokkai/iStock Unreleased via Getty Images\nInvestment Thesis\nSea Limited(NYSE:SE) stock is one of our highest conviction growth stocks that has been severely battered over the last month. Since its recent all-time high (ATH) in October, its price has dropped by a dramatic 43%. Many reasons have been presented on why the stock has fallen. We exhort investors not to read too much into them. We believe nothing material has changed from its fundamental thesis. The stock has had a remarkable run in 2021 relative to its gaming peers or e-tailer peers. Therefore, profit-taking of this extent should not be surprising as fear struck growth stocks.\nMoreover, the recent significant correction in growth stocks across the market has also hit SE stock hard. But, we are not concerned. Significant volatility will always be a factor influencing the performance of growth stocks like SE in the short term.\nNotably, we observed that the consensus target price on SE stock had been revised upwards since its FQ3 report card. Moreover, the gap between its price target and its current stock price has been greater than its last significant correction in April/May.\nOur internal DCF valuation model also points to a stock that is now significantly undervalued. Thanks to the market's myopia, we have been presented with another fantastic opportunity since April/May to add SE stock with great fervor again.\nWe discuss why we think investors should not miss this incredible opportunity to add exposure to an outstanding growth stock.\nSE Stock YTD Performance\nSE stock YTD performance (as of 17 December'21).\nAs a result of the significant correction recently, SE stock's YTD return has dropped to 6.9%, thus underperforming the market. Notably, its YTD gain was as high as 80% in October/early November. Despite that, the stock is still outperforming its e-tailer and gaming peers, as shown above.\nSea Stock Estimates Have Consistently Been Revised Upwards\nSea Limited revised revenue mean consensus estimates. Data source: S&P Capital IQ, Seeking Alpha\nReaders can quickly observe that the company's revenue consensus estimates for FY21-23 have consistently been revised upwards over the last five months. These revisions lend credence to the robust growth prospects of the company over the next two years. Notably, Sea Limited's revenue is estimated to increase at a phenomenal CAGR of 42.8% through FY23.\nThere were concerns over the growth rates of its Garena gaming arm in its FQ3 report card.We also explained in our previous article that Sea Limited has clearly explained that investors should expect normalization in Garena's growth after two spectacular years. However, its monetization capability continues to dazzle. Therefore, we are confident that Garena can continue its robust monetization strategies moving forward.\nMoreover, data from Sensor Tower's recent gaming statistics continue to point to sturdy performance from its Free Fire game. It continues to be ranked among the top ten mobile games in terms of overall gaming revenue in November. Moreover, it's also ranked#2 in overall downloadsacross both the App Store and Google Play. Notably, it's also among eight games globally whose annual revenue crossed $1B as of 14 December. Therefore, we think the sentiments and chatter about Free Fire's \"one-shot wonder\" have been overblown.\nGlobal games market forecast. Source: Google, Newzoo\nIn addition, the global gaming market is estimated to experience a slight decline to $175.8B after last year's massive 23% growth to $177.8B. However, given Garena's impressive growth in FY21 despite the decline in the global market, we believe it validates its business model and prospects. Notably, the gaming market is expected to reverse its decline moving forward. Therefore, Garena's leadership in mobile gaming could continue to propel its growth underpinned by the recovery in the global gaming market.\nShopee adjusted EBITDA per order. Data source: Company filings\nBut, some investors may have been spooked by Shopee's (Sea Limited's e-commerce arm) continued expansion into new geographical markets. Notably, Shopee continues to report adjusted EBITDA loss per order, as shown above. Therefore, some investors might have been concerned about whether the company's plate is getting too much to handle. Over the last three months, the company has entered into new markets such as India, France, Spain, and Poland. They are in addition to its battle with MercadoLibre (MELI) in Latin America, particularly Brazil. As a result, there are concerns on whether Sea Limited could continue its adroit execution in these markets while still making losses. We believe such concerns are valid. However, Sea Limited has shown its tremendous capability in penetrating the most important markets where the incumbents have strong leadership. It includes Lazada (BABA) in Southeast Asia, MercadoLibre in Brazil, and Tokopedia in Indonesia. Shopee was never the first-mover. But, it took advantage as the \"late-comer\" as it sought to compete with the incumbents. It's important to note that Sea Limited is not averse to competition. It has thrived against the incumbents and has made the e-commerce space in these geographical regions much more competitive.\nSea Limited revised adjusted EPS mean consensus estimates. Data source: S&P Capital IQ, Seeking Alpha\nNevertheless, the road towards profitability might be stretched further due to its e-commerce expansion. Readers can quickly glance over the chart above, where its adjusted EPS estimates have been revised downwards through FY23 over the last five months. However, we believe that if you are a long-term investor with a five-year horizon at least, it's not a cause for concern. Earlier investors in Sea Limited can keenly recall the company's massive adjusted EBITDA per order losses, as seen in the previous chart. Shopee has scaled tremendously over the last five years and has improved its operating leverage further. But, it's important to note that it takes time to scale up. Therefore, earlier losses in new geographical markets are expected. But, management has demonstrated its execution capability over the last three years. Considering its much reduced adjusted EBITDA losses over the previous few years, we believe that Shopee is even better positioned than before to navigate its expansion.\nSo, is SE Stock a Buy Now?\nSE stock EV/NTM Revenue 4Y mean.\nSE stock is trading at an EV/NTM Revenue of 8.3x. Therefore, it has brought it back to its 4Y NTM revenue multiple mean of 8.6x. We believe there's a fantastic opportunity right now as the market has undoubtedly overreacted. As demonstrated clearly, SE is still expected to generate massive revenue growth moving ahead, even though it means the road to profitability gets further extended.\nConsidering its FY23 revenue estimate, SE stock is trading at just 5.8x FY23 revenue. No one can accurately predict where the stock will be headed over the next few months. But, we think it represents a tremendous opportunity right now.\nSE stock price target Vs. actual price trend. Source: Seeking Alpha\nMoreover, readers can observe that the valuation gap between SE stock's consensus price target (PT) of $405.87 and its current price has never been more significant in a while. It's even more pronounced than its last significant correction in April/May. Notably, the consensus price target has been revised upwards despite the so-called \"gaming headwinds.\" And, if you look at the price chart, SE stock price has followed the revised PT trend very consistently over time. Therefore, the current price could be one of the most significant discounts you could observe in a long time.\nSE stock DCF valuation model. Data source: S&P Capital IQ, company filings, author\nOur DCF model also shows that SE stock is now significantly undervalued with an implied fair value of $371.46. We have also used reasonable estimates in our model. Moreover, we believe that SE will continue to gain significant operating leverage as it scales in the new markets. We estimate that its adjusted EBITDA margins could reach 15% by FY25.\nLastly, the stock is also testing a critical support level that has strongly underpinned the stock's advance since early 2021. Therefore, there are sufficient reasons to believe that the current entry point to add exposure to SE stock seems very attractive now.\nConsequently,we revise our rating on SE stock to Strong Buy.","news_type":1,"symbols_score_info":{"SE":0.9}},"isVote":1,"tweetType":1,"viewCount":3502,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699232578,"gmtCreate":1639805865423,"gmtModify":1639805865534,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089880892731870","idStr":"4089880892731870"},"themes":[],"title":"","htmlText":"mmmm&nbsp;","listText":"mmmm&nbsp;","text":"mmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699232578","repostId":"1109831591","repostType":4,"repost":{"id":"1109831591","kind":"news","pubTimestamp":1639804463,"share":"https://www.laohunote.com/m/news/1109831591?lang=zh_CN&edition=full","pubTime":"2021-12-18 13:14","market":"us","language":"en","title":"Why Pfizer and Johnson & Johnson Fell on Friday<blockquote>为什么辉瑞和强生公司周五下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1109831591","media":"Motley Fool","summary":"What happened\nTwo prominent U.S. coronavirus stocks ended the week on a down note. Pfizer and Johnso","content":"<p>What happened</p><p><blockquote>发生了什么事</blockquote></p><p> Two prominent U.S. coronavirus stocks ended the week on a down note.&nbsp;<a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>&nbsp;and&nbsp;<a href=\"https://laohu8.com/S/JNJ\"><b>Johnson &amp; Johnson</b></a>&nbsp;both fell on the day by nearly 3%. This followed a prominent investment bank's rather lukewarm take on their current prospects.</p><p><blockquote>两只著名的美国冠状病毒股票本周收盘下跌。<a href=\"https://laohu8.com/S/PFE\"><b>辉瑞</b></a>和<a href=\"https://laohu8.com/S/JNJ\"><b>强生公司</b></a>两者当天均下跌近3%。此前，一家著名投资银行对其当前前景持相当冷淡的态度。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c6a2f152eebbe10f5ab65a99815f461c\" tg-width=\"975\" tg-height=\"637\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> So what</p><p><blockquote>那又怎样</blockquote></p><p> <b>Goldman Sachs</b>&nbsp;analyst Chris Shibutani initiated coverage on Pfizer and Johnson &amp; Johnson on Friday, tagging both high-profile healthcare industry stocks with neutral recommendations.</p><p><blockquote><b>高盛</b>分析师克里斯·涩谷 (Chris Shibutani) 周五开始对辉瑞和强生公司进行报道，对这两只备受瞩目的医疗保健行业股票给予中性建议。</blockquote></p><p> Shibutani is concerned with what he considers to be Pfizer's somewhat cloudy future, despite the great success of the Comirnaty coronavirus vaccine it developed with Germanbiotech&nbsp;<b>BioNTech</b>.</p><p><blockquote>尽管辉瑞与德国生物技术公司合作开发的 Comirnaty 冠状病毒疫苗取得了巨大成功，但涩谷仍对他认为辉瑞有些模糊的未来感到担忧<b>生物技术</b>.</blockquote></p><p> \"Our views on [Pfizer] come down to that we estimate around one-third of its current valuation is attributed to the COVID-19 vaccine and therapeutic [products], and we feel the trajectory for both remains highly uncertain,\" he wrote.</p><p><blockquote>他写道：“我们对辉瑞的看法是，我们估计其当前估值的三分之一左右归因于 COVID-19 疫苗和治疗产品，我们认为两者的发展轨迹仍然高度不确定。”</blockquote></p><p> As for Johnson &amp; Johnson, the prognosticator feels the stock is also fairly valued. However, he sounded a more optimistic note about the company's potential.</p><p><blockquote>至于强生公司，预测者认为该股的估值也相当合理。然而，他对该公司的潜力表示了更乐观的态度。</blockquote></p><p> \"With [Johnson &amp; Johnson] in the midst of transitions across several domains for the organization ... we see possibilities -- even within an organization of [Johnson &amp; Johnson]'s scale and scope -- for additional potentially disruptive opportunities to develop that could reshape the investment thesis, in our view,\" he wrote.</p><p><blockquote>“随着 [强生] 正在组织的多个领域进行转型……我们看到了可能性——即使在 [强生] 规模和范围的组织内——额外的潜在颠覆性发展机会的可能性，我们认为，这可能会重塑投资论点，”他写道。</blockquote></p><p> Last month, Johnson &amp; Johnson announced plans to spin off its sprawlingconsumer healthcare division.</p><p><blockquote>上个月，强生公司宣布计划剥离其庞大的消费者医疗保健部门。</blockquote></p><p> Shibutani's price target on Pfizer stock is $51 per share, and that for Johnson &amp; Johnson is $161.</p><p><blockquote>涩谷对辉瑞股票的目标价为每股 51 美元，强生公司的目标价为每股 161 美元。</blockquote></p><p> Now what</p><p><blockquote>现在呢</blockquote></p><p> Pfizer and Johnson &amp; Johnson are certainly heading into some uncertain waters -- both with the coronavirus and, in the latter company's case, the apparently looming spinoff. To my mind, though, the two companies have plenty of strength in numerous product areas outside of their respective vaccines, so investors shouldn't be too discouraged by Goldman Sachs' latest evaluations.</p><p><blockquote>辉瑞（Pfizer）和强生公司（Johnson &amp; Johnson）无疑正进入一些不确定的水域——无论是冠状病毒，还是后者显然迫在眉睫的分拆。不过，在我看来，两家公司在各自疫苗之外的众多产品领域都拥有足够的实力，因此投资者不应对高盛的最新评估感到太气馁。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Pfizer and Johnson & Johnson Fell on Friday<blockquote>为什么辉瑞和强生公司周五下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Pfizer and Johnson & Johnson Fell on Friday<blockquote>为什么辉瑞和强生公司周五下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-12-18 13:14</span>\n</p>\n</h4>\n</header>\n<article>\n<p>What happened</p><p><blockquote>发生了什么事</blockquote></p><p> Two prominent U.S. coronavirus stocks ended the week on a down note.&nbsp;<a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>&nbsp;and&nbsp;<a href=\"https://laohu8.com/S/JNJ\"><b>Johnson &amp; Johnson</b></a>&nbsp;both fell on the day by nearly 3%. This followed a prominent investment bank's rather lukewarm take on their current prospects.</p><p><blockquote>两只著名的美国冠状病毒股票本周收盘下跌。<a href=\"https://laohu8.com/S/PFE\"><b>辉瑞</b></a>和<a href=\"https://laohu8.com/S/JNJ\"><b>强生公司</b></a>两者当天均下跌近3%。此前，一家著名投资银行对其当前前景持相当冷淡的态度。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c6a2f152eebbe10f5ab65a99815f461c\" tg-width=\"975\" tg-height=\"637\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> So what</p><p><blockquote>那又怎样</blockquote></p><p> <b>Goldman Sachs</b>&nbsp;analyst Chris Shibutani initiated coverage on Pfizer and Johnson &amp; Johnson on Friday, tagging both high-profile healthcare industry stocks with neutral recommendations.</p><p><blockquote><b>高盛</b>分析师克里斯·涩谷 (Chris Shibutani) 周五开始对辉瑞和强生公司进行报道，对这两只备受瞩目的医疗保健行业股票给予中性建议。</blockquote></p><p> Shibutani is concerned with what he considers to be Pfizer's somewhat cloudy future, despite the great success of the Comirnaty coronavirus vaccine it developed with Germanbiotech&nbsp;<b>BioNTech</b>.</p><p><blockquote>尽管辉瑞与德国生物技术公司合作开发的 Comirnaty 冠状病毒疫苗取得了巨大成功，但涩谷仍对他认为辉瑞有些模糊的未来感到担忧<b>生物技术</b>.</blockquote></p><p> \"Our views on [Pfizer] come down to that we estimate around one-third of its current valuation is attributed to the COVID-19 vaccine and therapeutic [products], and we feel the trajectory for both remains highly uncertain,\" he wrote.</p><p><blockquote>他写道：“我们对辉瑞的看法是，我们估计其当前估值的三分之一左右归因于 COVID-19 疫苗和治疗产品，我们认为两者的发展轨迹仍然高度不确定。”</blockquote></p><p> As for Johnson &amp; Johnson, the prognosticator feels the stock is also fairly valued. However, he sounded a more optimistic note about the company's potential.</p><p><blockquote>至于强生公司，预测者认为该股的估值也相当合理。然而，他对该公司的潜力表示了更乐观的态度。</blockquote></p><p> \"With [Johnson &amp; Johnson] in the midst of transitions across several domains for the organization ... we see possibilities -- even within an organization of [Johnson &amp; Johnson]'s scale and scope -- for additional potentially disruptive opportunities to develop that could reshape the investment thesis, in our view,\" he wrote.</p><p><blockquote>“随着 [强生] 正在组织的多个领域进行转型……我们看到了可能性——即使在 [强生] 规模和范围的组织内——额外的潜在颠覆性发展机会的可能性，我们认为，这可能会重塑投资论点，”他写道。</blockquote></p><p> Last month, Johnson &amp; Johnson announced plans to spin off its sprawlingconsumer healthcare division.</p><p><blockquote>上个月，强生公司宣布计划剥离其庞大的消费者医疗保健部门。</blockquote></p><p> Shibutani's price target on Pfizer stock is $51 per share, and that for Johnson &amp; Johnson is $161.</p><p><blockquote>涩谷对辉瑞股票的目标价为每股 51 美元，强生公司的目标价为每股 161 美元。</blockquote></p><p> Now what</p><p><blockquote>现在呢</blockquote></p><p> Pfizer and Johnson &amp; Johnson are certainly heading into some uncertain waters -- both with the coronavirus and, in the latter company's case, the apparently looming spinoff. To my mind, though, the two companies have plenty of strength in numerous product areas outside of their respective vaccines, so investors shouldn't be too discouraged by Goldman Sachs' latest evaluations.</p><p><blockquote>辉瑞（Pfizer）和强生公司（Johnson &amp; Johnson）无疑正进入一些不确定的水域——无论是冠状病毒，还是后者显然迫在眉睫的分拆。不过，在我看来，两家公司在各自疫苗之外的众多产品领域都拥有足够的实力，因此投资者不应对高盛的最新评估感到太气馁。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/12/17/why-pfizer-and-johnson-johnson-fell-on-friday/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/12/17/why-pfizer-and-johnson-johnson-fell-on-friday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109831591","content_text":"What happened\nTwo prominent U.S. coronavirus stocks ended the week on a down note. Pfizer and Johnson & Johnson both fell on the day by nearly 3%. This followed a prominent investment bank's rather lukewarm take on their current prospects.\n\nSo what\nGoldman Sachs analyst Chris Shibutani initiated coverage on Pfizer and Johnson & Johnson on Friday, tagging both high-profile healthcare industry stocks with neutral recommendations.\nShibutani is concerned with what he considers to be Pfizer's somewhat cloudy future, despite the great success of the Comirnaty coronavirus vaccine it developed with Germanbiotech BioNTech.\n\"Our views on [Pfizer] come down to that we estimate around one-third of its current valuation is attributed to the COVID-19 vaccine and therapeutic [products], and we feel the trajectory for both remains highly uncertain,\" he wrote.\nAs for Johnson & Johnson, the prognosticator feels the stock is also fairly valued. However, he sounded a more optimistic note about the company's potential.\n\"With [Johnson & Johnson] in the midst of transitions across several domains for the organization ... we see possibilities -- even within an organization of [Johnson & Johnson]'s scale and scope -- for additional potentially disruptive opportunities to develop that could reshape the investment thesis, in our view,\" he wrote.\nLast month, Johnson & Johnson announced plans to spin off its sprawlingconsumer healthcare division.\nShibutani's price target on Pfizer stock is $51 per share, and that for Johnson & Johnson is $161.\nNow what\nPfizer and Johnson & Johnson are certainly heading into some uncertain waters -- both with the coronavirus and, in the latter company's case, the apparently looming spinoff. To my mind, though, the two companies have plenty of strength in numerous product areas outside of their respective vaccines, so investors shouldn't be too discouraged by Goldman Sachs' latest evaluations.","news_type":1,"symbols_score_info":{"PFE":0.9,"JNJ":0.9}},"isVote":1,"tweetType":1,"viewCount":3122,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699238053,"gmtCreate":1639805119710,"gmtModify":1639805119710,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089880892731870","idStr":"4089880892731870"},"themes":[],"title":"","htmlText":"buy at dip?&nbsp;[Cool]&nbsp;","listText":"buy at dip?&nbsp;[Cool]&nbsp;","text":"buy at dip? [Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699238053","repostId":"1113352768","repostType":4,"repost":{"id":"1113352768","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639752492,"share":"https://www.laohunote.com/m/news/1113352768?lang=zh_CN&edition=full","pubTime":"2021-12-17 22:48","market":"us","language":"en","title":"Amazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group<blockquote>印度暂停与 Future Group 2019 年的交易，亚马逊早盘下跌近 2%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1113352768","media":"Tiger Newspress","summary":"Amazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group.India's ","content":"<p>Amazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group.<img src=\"https://static.tigerbbs.com/ecaa54686b8d8b0541b8769a2aa237a3\" tg-width=\"766\" tg-height=\"567\" width=\"100%\" height=\"auto\">India's antitrust body on Friday suspended Amazon.com's 2019 deal with Future Group following a review of allegations that the U.S. e-commerce giant had concealed information while seeking regulatory approval.</p><p><blockquote>由于印度暂停了与 Future Group 2019 年的交易，亚马逊在早盘交易中下跌近 2%。印度反垄断机构周五暂停了亚马逊 2019 年与 Future Group 的交易，此前该机构审查了有关这家美国电子商务巨头在寻求监管部门批准时隐瞒信息的指控。</blockquote></p><p> The unprecedented step taken by the Competition Commission of India (CCI) could have far-reaching consequences on Amazon's legal battles with now estranged partner Future. The U.S. firm has for months successfully used the terms of its toehold $200 million investment in 2019 to block Future's attempt to sell retail assets to Reliance Industries for $3.4 billion.</p><p><blockquote>印度竞争委员会（CCI）采取的史无前例的举措可能会对亚马逊与现已疏远的合作伙伴Future的法律诉讼产生深远的影响。几个月来，这家美国公司成功地利用其 2019 年 2 亿美元投资的条款，阻止 Future 以 34 亿美元的价格向 Reliance Industries 出售零售资产的企图。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group<blockquote>印度暂停与 Future Group 2019 年的交易，亚马逊早盘下跌近 2%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group<blockquote>印度暂停与 Future Group 2019 年的交易，亚马逊早盘下跌近 2%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-17 22:48</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Amazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group.<img src=\"https://static.tigerbbs.com/ecaa54686b8d8b0541b8769a2aa237a3\" tg-width=\"766\" tg-height=\"567\" width=\"100%\" height=\"auto\">India's antitrust body on Friday suspended Amazon.com's 2019 deal with Future Group following a review of allegations that the U.S. e-commerce giant had concealed information while seeking regulatory approval.</p><p><blockquote>由于印度暂停了与 Future Group 2019 年的交易，亚马逊在早盘交易中下跌近 2%。印度反垄断机构周五暂停了亚马逊 2019 年与 Future Group 的交易，此前该机构审查了有关这家美国电子商务巨头在寻求监管部门批准时隐瞒信息的指控。</blockquote></p><p> The unprecedented step taken by the Competition Commission of India (CCI) could have far-reaching consequences on Amazon's legal battles with now estranged partner Future. The U.S. firm has for months successfully used the terms of its toehold $200 million investment in 2019 to block Future's attempt to sell retail assets to Reliance Industries for $3.4 billion.</p><p><blockquote>印度竞争委员会（CCI）采取的史无前例的举措可能会对亚马逊与现已疏远的合作伙伴Future的法律诉讼产生深远的影响。几个月来，这家美国公司成功地利用其 2019 年 2 亿美元投资的条款，阻止 Future 以 34 亿美元的价格向 Reliance Industries 出售零售资产的企图。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113352768","content_text":"Amazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group.India's antitrust body on Friday suspended Amazon.com's 2019 deal with Future Group following a review of allegations that the U.S. e-commerce giant had concealed information while seeking regulatory approval.\nThe unprecedented step taken by the Competition Commission of India (CCI) could have far-reaching consequences on Amazon's legal battles with now estranged partner Future. The U.S. firm has for months successfully used the terms of its toehold $200 million investment in 2019 to block Future's attempt to sell retail assets to Reliance Industries for $3.4 billion.","news_type":1,"symbols_score_info":{"AMZN":0.9}},"isVote":1,"tweetType":1,"viewCount":3434,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602453657,"gmtCreate":1639060563339,"gmtModify":1639061378393,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089880892731870","idStr":"4089880892731870"},"themes":[],"title":"","htmlText":"very insightful article and shed some light on why&nbsp;<a href=\"https://laohu8.com/S/GRAB\">$Grab Holdings(GRAB)$</a>is doing so badly. only wish it came out earlier&nbsp;[Cry]&nbsp;","listText":"very insightful article and shed some light on why&nbsp;<a href=\"https://laohu8.com/S/GRAB\">$Grab Holdings(GRAB)$</a>is doing so badly. only wish it came out earlier&nbsp;[Cry]&nbsp;","text":"very insightful article and shed some light on why $Grab Holdings(GRAB)$is doing so badly. only wish it came out earlier [Cry]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/602453657","repostId":"2190614747","repostType":2,"isVote":1,"tweetType":1,"viewCount":5551,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602468206,"gmtCreate":1639058758922,"gmtModify":1639059675097,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089880892731870","idStr":"4089880892731870"},"themes":[],"title":"","htmlText":"wanted to buy the dip but there isn't really a dip with&nbsp;[LOL]&nbsp;","listText":"wanted to buy the dip but there isn't really a dip with&nbsp;[LOL]&nbsp;","text":"wanted to buy the dip but there isn't really a dip with [LOL]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/602468206","repostId":"1129645066","repostType":4,"repost":{"id":"1129645066","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639053071,"share":"https://www.laohunote.com/m/news/1129645066?lang=zh_CN&edition=full","pubTime":"2021-12-09 20:31","market":"us","language":"en","title":"Amazon shares fell slightly by 0.5% in premarket trading<blockquote>亚马逊股价在盘前交易中小幅下跌 0.5%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1129645066","media":"Tiger Newspress","summary":"Amazon shares fell slightly by 0.5% in premarket trading after Italy's antitrust fined Amazon 1.13 b","content":"<p>Amazon shares fell slightly by 0.5% in premarket trading&nbsp;after&nbsp;Italy's antitrust fined Amazon 1.13 bln euros for alleged abuse of market dominance.</p><p><blockquote>在意大利反垄断机构因涉嫌滥用市场支配地位对亚马逊处以 11.3 亿欧元罚款后，亚马逊股价在盘前交易中小幅下跌 0.5%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/1aa0616746882964f5e05a784287edeb\" tg-width=\"850\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Italy's antitrust said on Thursday it had fined e-commerce giant Amazon 1.13 billion euros ($1.28 billion) for alleged abuse of market dominance.</p><p><blockquote>意大利反垄断机构周四表示，因涉嫌滥用市场支配地位，已对电子商务巨头亚马逊处以 11.3 亿欧元（12.8 亿美元）的罚款。</blockquote></p><p> In a statement the watchdog said Amazon had harmed competing operators in the e-commerce logistics service.</p><p><blockquote>该监管机构在一份声明中表示，亚马逊损害了电子商务物流服务领域的竞争运营商。</blockquote></p><p> \"Amazon holds a dominant position in the Italian market for intermediation services on marketplaces, which Amazon leveraged to favour the adoption of its own logistics service - Fulfilment by Amazon (FBA) - by sellers active on Amazon.it to the detriment of the logistics services offered by competing operators, as well as to strengthen its own dominant position,\" it added.</p><p><blockquote>“亚马逊在意大利市场中介服务市场上占据主导地位，亚马逊利用这一点来鼓励活跃在亚马逊上的卖家采用自己的物流服务——亚马逊履行（FBA）。这损害了竞争对手提供的物流服务运营商，以及加强自己的主导地位，”它补充道。</blockquote></p><p> The antitrust said it would impose on Amazon corrective steps that will be subject to review by a monitoring trustee.</p><p><blockquote>该反垄断机构表示，将对亚马逊采取纠正措施，并接受监控受托人的审查。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amazon shares fell slightly by 0.5% in premarket trading<blockquote>亚马逊股价在盘前交易中小幅下跌 0.5%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmazon shares fell slightly by 0.5% in premarket trading<blockquote>亚马逊股价在盘前交易中小幅下跌 0.5%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-09 20:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Amazon shares fell slightly by 0.5% in premarket trading&nbsp;after&nbsp;Italy's antitrust fined Amazon 1.13 bln euros for alleged abuse of market dominance.</p><p><blockquote>在意大利反垄断机构因涉嫌滥用市场支配地位对亚马逊处以 11.3 亿欧元罚款后，亚马逊股价在盘前交易中小幅下跌 0.5%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/1aa0616746882964f5e05a784287edeb\" tg-width=\"850\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Italy's antitrust said on Thursday it had fined e-commerce giant Amazon 1.13 billion euros ($1.28 billion) for alleged abuse of market dominance.</p><p><blockquote>意大利反垄断机构周四表示，因涉嫌滥用市场支配地位，已对电子商务巨头亚马逊处以 11.3 亿欧元（12.8 亿美元）的罚款。</blockquote></p><p> In a statement the watchdog said Amazon had harmed competing operators in the e-commerce logistics service.</p><p><blockquote>该监管机构在一份声明中表示，亚马逊损害了电子商务物流服务领域的竞争运营商。</blockquote></p><p> \"Amazon holds a dominant position in the Italian market for intermediation services on marketplaces, which Amazon leveraged to favour the adoption of its own logistics service - Fulfilment by Amazon (FBA) - by sellers active on Amazon.it to the detriment of the logistics services offered by competing operators, as well as to strengthen its own dominant position,\" it added.</p><p><blockquote>“亚马逊在意大利市场中介服务市场上占据主导地位，亚马逊利用这一点来鼓励活跃在亚马逊上的卖家采用自己的物流服务——亚马逊履行（FBA）。这损害了竞争对手提供的物流服务运营商，以及加强自己的主导地位，”它补充道。</blockquote></p><p> The antitrust said it would impose on Amazon corrective steps that will be subject to review by a monitoring trustee.</p><p><blockquote>该反垄断机构表示，将对亚马逊采取纠正措施，并接受监控受托人的审查。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129645066","content_text":"Amazon shares fell slightly by 0.5% in premarket trading after Italy's antitrust fined Amazon 1.13 bln euros for alleged abuse of market dominance.\n\nItaly's antitrust said on Thursday it had fined e-commerce giant Amazon 1.13 billion euros ($1.28 billion) for alleged abuse of market dominance.\nIn a statement the watchdog said Amazon had harmed competing operators in the e-commerce logistics service.\n\"Amazon holds a dominant position in the Italian market for intermediation services on marketplaces, which Amazon leveraged to favour the adoption of its own logistics service - Fulfilment by Amazon (FBA) - by sellers active on Amazon.it to the detriment of the logistics services offered by competing operators, as well as to strengthen its own dominant position,\" it added.\nThe antitrust said it would impose on Amazon corrective steps that will be subject to review by a monitoring trustee.","news_type":1,"symbols_score_info":{"AMZN":0.9}},"isVote":1,"tweetType":1,"viewCount":3491,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602132570,"gmtCreate":1638979550717,"gmtModify":1638979550717,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089880892731870","idStr":"4089880892731870"},"themes":[],"title":"","htmlText":"to the moon!&nbsp;[Cool]&nbsp;[Cool]&nbsp;","listText":"to the moon!&nbsp;[Cool]&nbsp;[Cool]&nbsp;","text":"to the moon! [Cool] [Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/602132570","repostId":"1161444269","repostType":4,"repost":{"id":"1161444269","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638977215,"share":"https://www.laohunote.com/m/news/1161444269?lang=zh_CN&edition=full","pubTime":"2021-12-08 23:26","market":"us","language":"en","title":"Apple shares rose nearly 2% to a new high<blockquote>苹果股价上涨近2%创新高</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1161444269","media":"Tiger Newspress","summary":"Apple shares rose nearly 2% to a new high in morning trading.","content":"<p>Apple shares rose nearly 2% to a new high&nbsp;in morning trading.</p><p><blockquote>苹果股价在早盘交易中上涨近2%，创下新高。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/9a9f5fdc1cb0a898675c515a39de7611\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple shares rose nearly 2% to a new high<blockquote>苹果股价上涨近2%创新高</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple shares rose nearly 2% to a new high<blockquote>苹果股价上涨近2%创新高</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-08 23:26</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Apple shares rose nearly 2% to a new high&nbsp;in morning trading.</p><p><blockquote>苹果股价在早盘交易中上涨近2%，创下新高。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/9a9f5fdc1cb0a898675c515a39de7611\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161444269","content_text":"Apple shares rose nearly 2% to a new high in morning trading.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":4629,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602136955,"gmtCreate":1638979419776,"gmtModify":1638979419884,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089880892731870","idStr":"4089880892731870"},"themes":[],"title":"","htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602136955","repostId":"1177589023","repostType":4,"repost":{"id":"1177589023","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638964838,"share":"https://www.laohunote.com/m/news/1177589023?lang=zh_CN&edition=full","pubTime":"2021-12-08 20:00","market":"us","language":"en","title":"Pfizer, BioNTech say third dose neutralizes Omicron variant<blockquote>辉瑞、BioNTech 表示第三剂疫苗中和了奥密克戎变种</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1177589023","media":"Tiger Newspress","summary":"Pfizer and biontech stocks narrowed their losses in premarket trading after they provided update on ","content":"<p>Pfizer and biontech stocks narrowed their losses&nbsp;in premarket trading&nbsp;after&nbsp;they provided update on Omicron variant.</p><p><blockquote>辉瑞和 biontech 股票在提供有关奥密克戎变种的最新信息后，在盘前交易中缩小了跌幅。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/896ce4e657b0942d9d7a0abce1c3d2f7\" tg-width=\"853\" tg-height=\"622\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/35c4bf42aa2936640aedd52e01beebc5\" tg-width=\"853\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <ul>  <li><i>Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers</i></li>  <li><i>Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection</i></li>  <li><i>As 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease</i></li>  <li><i>The companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022</i></li> </ul> Pfizer Inc.&nbsp;and&nbsp;BioNTech SE&nbsp;today announced results from an initial&nbsp;<i>laboratory</i>&nbsp;study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.</p><p><blockquote><ul><li><i>初步实验室研究表明，三剂辉瑞-BioNTech新冠肺炎疫苗中和奥密克戎变异株（B.1.1.529谱系），而两剂显示出中和滴度显著降低</i></li><li><i>数据表明，与针对奥密克戎变体的两个剂量相比，第三剂量的BNT162b2将中和抗体滴度增加25倍；加强剂量后的滴度与针对野生型病毒的两次剂量后观察到的滴度相当，这与高水平的保护相关</i></li><li><i>由于CD8+T细胞识别的刺突蛋白中80%的表位不受奥密克戎变体中突变的影响，两个剂量仍然可以诱导对严重疾病的保护</i></li><li><i>两家公司将继续推进针对奥密克戎病毒的变种特异性疫苗的开发，如果需要进行调整以进一步提高保护水平和持续时间，预计将于 3 月份上市--预计两家公司 2022 年 40 亿剂疫苗的产能不会发生变化。</i></li></ul>辉瑞公司和 BioNTech SE 今天公布了初步结果<i>实验室</i>研究表明，辉瑞-BioNTech新冠肺炎疫苗（BNT162b2）诱导的血清抗体在接种三剂后中和新型冠状病毒奥密克戎变体。在接受加强疫苗接种（第三剂BNT162b2疫苗）一个月后从接种者获得的血清中和了奥密克戎变异体，其水平与两剂后野生型新型冠状病毒刺突蛋白相当。</blockquote></p><p> Sera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.</p><p><blockquote>与野生型相比，接受两剂当前新冠肺炎疫苗的个体的血清确实显示，与野生型相比，针对奥密克戎变体的中和滴度平均降低了25倍以上，这表明两剂BNT162b2可能不足以预防感染奥密克戎变体。然而，由于疫苗诱导的T细胞靶向的绝大多数表位不受奥密克戎突变的影响，这些公司认为，接种疫苗的个体仍然可以免受严重形式的疾病的侵害，并正在密切监测全球范围内针对奥密克戎的现实效果。</blockquote></p><p> A more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.</p><p><blockquote>第三剂可以实现更强大的保护，因为两家公司的其他研究数据表明，辉瑞和 BioNTech 当前 COVID-19 疫苗的加强剂可将抗体滴度提高 25 倍。根据两家公司的初步数据，第三剂疫苗对奥密克戎病毒的中和抗体水平与对野生型病毒和奥密克戎病毒之前出现的其他变种疫苗接种两剂疫苗后观察到的水平相似。这些抗体水平与针对野生型病毒和这些变体的高功效相关。第三剂还强烈增加针对多个刺突蛋白表位的CD8+T细胞水平，这些刺突蛋白表位被认为与对严重疾病的保护相关。与野生型病毒相比，这些表位的绝大多数在奥密克戎刺突变体中保持不变。</blockquote></p><p> “Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said&nbsp;<b>Albert Bourla, Chairman and Chief Executive Officer, Pfizer</b>. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”</p><p><blockquote>“虽然接种两剂疫苗仍能预防奥密克戎毒株引起的严重疾病，但从这些初步数据来看，接种第三剂疫苗可以提高保护能力，”他说。<b>Albert Bourla，辉瑞公司董事长兼首席执行官</b>. “确保尽可能多的人完全接种前两剂疫苗和加强针仍然是防止 COVID-19 传播的最佳行动方案”。</blockquote></p><p> “Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said&nbsp;<b>Ugur Sahin, M.D., CEO and Co-Founder of BioNTech</b>. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”</p><p><blockquote>“我们初步的第一批数据集表明，第三剂疫苗仍能提供足够的保护，预防奥密克戎变异株引起的任何严重程度的疾病。”<b>Ugur Sahin，医学博士，BioNTech 首席执行官兼联合创始人</b>. “在世界各地开展广泛的疫苗接种和加强运动可以帮助我们更好地保护各地的人们，并帮助他们度过冬季。我们将继续研发一种经过改造的疫苗，我们相信，与目前的疫苗相比，这种疫苗将有助于对奥密克戎引起的 COVID-19 疾病产生高水平的保护作用，并提供更持久的保护”。</blockquote></p><p></p><p> While these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta &amp; Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.</p><p><blockquote>虽然这些结果是初步的，但这些公司将继续收集更多的实验室数据并评估现实世界的有效性，以评估和确认对奥密克戎的保护，并为最有效的前进道路提供信息。11月25日，两家公司开始开发奥密克戎特异性新冠肺炎疫苗。如果需要调整疫苗以提高对奥密克戎的保护水平和持续时间，开发将按计划继续进行。第一批总部位于奥密克戎的疫苗可以生产，并计划在100天内准备好交付，等待监管部门的批准。辉瑞和BioNTech也测试了其他变异特异性疫苗，这些疫苗产生了非常强的中和滴度和可耐受的安全性。基于这一经验，这些公司非常有信心，如果需要的话，他们可以在2022年3月交付基于奥密克戎的疫苗。这些公司此前还启动了变异特异性疫苗（Alpha、Beta、DeltaΑ/Delta混合）的临床试验，这些研究的数据将提交给世界各地的监管机构，以帮助加快疫苗的适应过程，并在需要时获得奥密克戎特异性疫苗的监管授权或批准。这两家公司此前曾宣布，他们预计将在2022年生产40亿剂BNT162b2，如果需要适应的疫苗，这一产能预计不会改变。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer, BioNTech say third dose neutralizes Omicron variant<blockquote>辉瑞、BioNTech 表示第三剂疫苗中和了奥密克戎变种</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer, BioNTech say third dose neutralizes Omicron variant<blockquote>辉瑞、BioNTech 表示第三剂疫苗中和了奥密克戎变种</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-08 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Pfizer and biontech stocks narrowed their losses&nbsp;in premarket trading&nbsp;after&nbsp;they provided update on Omicron variant.</p><p><blockquote>辉瑞和 biontech 股票在提供有关奥密克戎变种的最新信息后，在盘前交易中缩小了跌幅。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/896ce4e657b0942d9d7a0abce1c3d2f7\" tg-width=\"853\" tg-height=\"622\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/35c4bf42aa2936640aedd52e01beebc5\" tg-width=\"853\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <ul>  <li><i>Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers</i></li>  <li><i>Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection</i></li>  <li><i>As 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease</i></li>  <li><i>The companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022</i></li> </ul> Pfizer Inc.&nbsp;and&nbsp;BioNTech SE&nbsp;today announced results from an initial&nbsp;<i>laboratory</i>&nbsp;study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.</p><p><blockquote><ul><li><i>初步实验室研究表明，三剂辉瑞-BioNTech新冠肺炎疫苗中和奥密克戎变异株（B.1.1.529谱系），而两剂显示出中和滴度显著降低</i></li><li><i>数据表明，与针对奥密克戎变体的两个剂量相比，第三剂量的BNT162b2将中和抗体滴度增加25倍；加强剂量后的滴度与针对野生型病毒的两次剂量后观察到的滴度相当，这与高水平的保护相关</i></li><li><i>由于CD8+T细胞识别的刺突蛋白中80%的表位不受奥密克戎变体中突变的影响，两个剂量仍然可以诱导对严重疾病的保护</i></li><li><i>两家公司将继续推进针对奥密克戎病毒的变种特异性疫苗的开发，如果需要进行调整以进一步提高保护水平和持续时间，预计将于 3 月份上市--预计两家公司 2022 年 40 亿剂疫苗的产能不会发生变化。</i></li></ul>辉瑞公司和 BioNTech SE 今天公布了初步结果<i>实验室</i>研究表明，辉瑞-BioNTech新冠肺炎疫苗（BNT162b2）诱导的血清抗体在接种三剂后中和新型冠状病毒奥密克戎变体。在接受加强疫苗接种（第三剂BNT162b2疫苗）一个月后从接种者获得的血清中和了奥密克戎变异体，其水平与两剂后野生型新型冠状病毒刺突蛋白相当。</blockquote></p><p> Sera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.</p><p><blockquote>与野生型相比，接受两剂当前新冠肺炎疫苗的个体的血清确实显示，与野生型相比，针对奥密克戎变体的中和滴度平均降低了25倍以上，这表明两剂BNT162b2可能不足以预防感染奥密克戎变体。然而，由于疫苗诱导的T细胞靶向的绝大多数表位不受奥密克戎突变的影响，这些公司认为，接种疫苗的个体仍然可以免受严重形式的疾病的侵害，并正在密切监测全球范围内针对奥密克戎的现实效果。</blockquote></p><p> A more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.</p><p><blockquote>第三剂可以实现更强大的保护，因为两家公司的其他研究数据表明，辉瑞和 BioNTech 当前 COVID-19 疫苗的加强剂可将抗体滴度提高 25 倍。根据两家公司的初步数据，第三剂疫苗对奥密克戎病毒的中和抗体水平与对野生型病毒和奥密克戎病毒之前出现的其他变种疫苗接种两剂疫苗后观察到的水平相似。这些抗体水平与针对野生型病毒和这些变体的高功效相关。第三剂还强烈增加针对多个刺突蛋白表位的CD8+T细胞水平，这些刺突蛋白表位被认为与对严重疾病的保护相关。与野生型病毒相比，这些表位的绝大多数在奥密克戎刺突变体中保持不变。</blockquote></p><p> “Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said&nbsp;<b>Albert Bourla, Chairman and Chief Executive Officer, Pfizer</b>. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”</p><p><blockquote>“虽然接种两剂疫苗仍能预防奥密克戎毒株引起的严重疾病，但从这些初步数据来看，接种第三剂疫苗可以提高保护能力，”他说。<b>Albert Bourla，辉瑞公司董事长兼首席执行官</b>. “确保尽可能多的人完全接种前两剂疫苗和加强针仍然是防止 COVID-19 传播的最佳行动方案”。</blockquote></p><p> “Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said&nbsp;<b>Ugur Sahin, M.D., CEO and Co-Founder of BioNTech</b>. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”</p><p><blockquote>“我们初步的第一批数据集表明，第三剂疫苗仍能提供足够的保护，预防奥密克戎变异株引起的任何严重程度的疾病。”<b>Ugur Sahin，医学博士，BioNTech 首席执行官兼联合创始人</b>. “在世界各地开展广泛的疫苗接种和加强运动可以帮助我们更好地保护各地的人们，并帮助他们度过冬季。我们将继续研发一种经过改造的疫苗，我们相信，与目前的疫苗相比，这种疫苗将有助于对奥密克戎引起的 COVID-19 疾病产生高水平的保护作用，并提供更持久的保护”。</blockquote></p><p></p><p> While these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta &amp; Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.</p><p><blockquote>虽然这些结果是初步的，但这些公司将继续收集更多的实验室数据并评估现实世界的有效性，以评估和确认对奥密克戎的保护，并为最有效的前进道路提供信息。11月25日，两家公司开始开发奥密克戎特异性新冠肺炎疫苗。如果需要调整疫苗以提高对奥密克戎的保护水平和持续时间，开发将按计划继续进行。第一批总部位于奥密克戎的疫苗可以生产，并计划在100天内准备好交付，等待监管部门的批准。辉瑞和BioNTech也测试了其他变异特异性疫苗，这些疫苗产生了非常强的中和滴度和可耐受的安全性。基于这一经验，这些公司非常有信心，如果需要的话，他们可以在2022年3月交付基于奥密克戎的疫苗。这些公司此前还启动了变异特异性疫苗（Alpha、Beta、DeltaΑ/Delta混合）的临床试验，这些研究的数据将提交给世界各地的监管机构，以帮助加快疫苗的适应过程，并在需要时获得奥密克戎特异性疫苗的监管授权或批准。这两家公司此前曾宣布，他们预计将在2022年生产40亿剂BNT162b2，如果需要适应的疫苗，这一产能预计不会改变。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1177589023","content_text":"Pfizer and biontech stocks narrowed their losses in premarket trading after they provided update on Omicron variant.\n\n\nPreliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers\nData indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection\nAs 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease\nThe companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022\n\nPfizer Inc. and BioNTech SE today announced results from an initial laboratory study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.\nSera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.\nA more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.\n“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”\n“Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”\nWhile these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta & Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.","news_type":1,"symbols_score_info":{"BNTX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":3447,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603647269,"gmtCreate":1638408688437,"gmtModify":1638413365848,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089880892731870","idStr":"4089880892731870"},"themes":[],"title":"","htmlText":"It's really interesting to note that&nbsp;<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>is clearly needed worldwide but yet its share is still&nbsp;[Speechless]&nbsp;[Speechless]&nbsp;","listText":"It's really interesting to note that&nbsp;<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>is clearly needed worldwide but yet its share is still&nbsp;[Speechless]&nbsp;[Speechless]&nbsp;","text":"It's really interesting to note that $Moderna, Inc.(MRNA)$is clearly needed worldwide but yet its share is still [Speechless] [Speechless]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603647269","repostId":"2188560153","repostType":2,"isVote":1,"tweetType":1,"viewCount":3207,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603132509,"gmtCreate":1638372243529,"gmtModify":1638372243668,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089880892731870","idStr":"4089880892731870"},"themes":[],"title":"","htmlText":"A good time to buy in&nbsp;<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>[Cool]&nbsp;","listText":"A good time to buy in&nbsp;<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>[Cool]&nbsp;","text":"A good time to buy in $Sea Ltd(SE)$[Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603132509","repostId":"2186310769","repostType":2,"isVote":1,"tweetType":1,"viewCount":3887,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600550505,"gmtCreate":1638177679665,"gmtModify":1638177748090,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089880892731870","idStr":"4089880892731870"},"themes":[],"title":"","htmlText":"[财迷]&nbsp;","listText":"[财迷]&nbsp;","text":"[财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600550505","repostId":"1106015985","repostType":2,"repost":{"id":"1106015985","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638176514,"share":"https://www.laohunote.com/m/news/1106015985?lang=zh_CN&edition=full","pubTime":"2021-11-29 17:01","market":"us","language":"en","title":"Moderna stock surged 8% in premarket trading<blockquote>Moderna 股价在盘前交易中飙升 8%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1106015985","media":"Tiger Newspress","summary":"Moderna stock surged 8% in premarket trading as it said new covid-19 vaccine for Omicron might be re","content":"<p>Moderna stock surged 8% in premarket trading&nbsp;as&nbsp;it&nbsp;said new covid-19 vaccine for Omicron might be ready in early 2022.</p><p><blockquote>Moderna 股价在盘前交易中飙升 8%，因为该公司表示奥密克戎的新型 covid-19 疫苗可能会在 2022 年初准备就绪。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/660e8ece7a2b338498e4bfe9f3c38228\" tg-width=\"851\" tg-height=\"616\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Moderna&nbsp;chief medical officer Paul Burton said he suspects the new Omicron coronavirus variant may elude current vaccines, and if so, a reformulated shot could be available early in the new year.</p><p><blockquote>Moderna首席医疗官Paul Burton表示，他怀疑新的奥密克戎冠状病毒变种可能会躲过当前的疫苗，如果是这样，重新配制的疫苗可能会在新年伊始上市。</blockquote></p><p> \"We should know about the ability of the current vaccine to provide protection in the next couple of weeks,\" Mr Burton said on Sunday (Nov 28) on the BBC's Andrew Marr Show.</p><p><blockquote>伯顿周日（11 月 28 日）在 BBC 安德鲁·马尔秀节目中表示：“我们应该了解当前疫苗在未来几周内提供保护的能力。”</blockquote></p><p> \"If we have to make a brand new vaccine, I think that's going to be early 2022 before that's really going to be available in large quantities,\" he said.</p><p><blockquote>“如果我们必须制造一种全新的疫苗，我认为要到 2022 年初才能真正大量上市，”他说。</blockquote></p><p> \"The remarkable thing about the mRNA vaccines, the Moderna platform, is that we can move very fast,\" he added.</p><p><blockquote>“mRNA 疫苗（Moderna 平台）的非凡之处在于我们可以非常快速地移动，”他补充道。</blockquote></p><p> The Cambridge, Massachusetts-based biotech company mobilised \"hundreds\" of staff early last&nbsp;Thursday, Thanksgiving Day in the United States, after news of the Omicron variant spread.</p><p><blockquote>上周四美国感恩节早些时候，在奥密克戎变种病毒的消息传开后，这家总部位于马萨诸塞州剑桥的生物技术公司动员了“数百名”员工。</blockquote></p><p> Protection should still exist, depending on how long ago a person was vaccinated, and for now the best advice is to take one of the current Covid-19 vaccines, Mr Burton said.</p><p><blockquote>伯顿先生说，保护应该仍然存在，这取决于一个人接种疫苗的时间，目前最好的建议是接种当前的 Covid-19 疫苗之一。</blockquote></p><p> \"If people are on the fence, and you haven't been vaccinated, get vaccinated,\" he said. \"This is a dangerous-looking virus, but I think we have many tools in our armamentarium now to fight it.\"</p><p><blockquote>“如果人们持观望态度，而你还没有接种疫苗，那就接种疫苗，”他说。“这是一种看起来很危险的病毒，但我认为我们现在的武器库中有很多工具可以对抗它。”</blockquote></p><p> The emergence of the Omicron strain has seen countries rush to clamp down on travel from southern Africa.</p><p><blockquote>奥密克戎病毒的出现导致各国急于限制来自南部非洲的旅行。</blockquote></p><p> Fears that it could exacerbate a winter Covid-19 surge in the northern hemisphere and undermine a global economic recovery sent a wave of risk aversion across global markets last&nbsp;Friday that continued on Sunday when the Middle East opened for the week.</p><p><blockquote>上周五，由于担心这可能会加剧北半球冬季新冠肺炎疫情激增并破坏全球经济复苏，全球市场掀起了一波避险情绪，这种情绪在周日中东开盘时仍在继续。</blockquote></p><p> Moderna said in a release on Friday that it was working rapidly to test the current vaccine against the Omicron variant, and studying two booster candidates.</p><p><blockquote>Moderna在周五的一份新闻稿中表示，它正在快速测试当前针对奥密克戎变种的疫苗，并研究两种候选加强剂。</blockquote></p><p> \"Since early 2021, Moderna has advanced a comprehensive strategy to anticipate new variants of concern,\" the company said. \"The company has repeatedly demonstrated the ability to advance new candidates to clinical testing in 60 to 90 days.\"</p><p><blockquote>该公司表示：“自 2021 年初以来，Moderna 已推进一项全面战略，以预测令人担忧的新变种。”“该公司已多次证明有能力在 60 至 90 天内将新候选药物推进临床试验。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock surged 8% in premarket trading<blockquote>Moderna 股价在盘前交易中飙升 8%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock surged 8% in premarket trading<blockquote>Moderna 股价在盘前交易中飙升 8%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 17:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Moderna stock surged 8% in premarket trading&nbsp;as&nbsp;it&nbsp;said new covid-19 vaccine for Omicron might be ready in early 2022.</p><p><blockquote>Moderna 股价在盘前交易中飙升 8%，因为该公司表示奥密克戎的新型 covid-19 疫苗可能会在 2022 年初准备就绪。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/660e8ece7a2b338498e4bfe9f3c38228\" tg-width=\"851\" tg-height=\"616\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Moderna&nbsp;chief medical officer Paul Burton said he suspects the new Omicron coronavirus variant may elude current vaccines, and if so, a reformulated shot could be available early in the new year.</p><p><blockquote>Moderna首席医疗官Paul Burton表示，他怀疑新的奥密克戎冠状病毒变种可能会躲过当前的疫苗，如果是这样，重新配制的疫苗可能会在新年伊始上市。</blockquote></p><p> \"We should know about the ability of the current vaccine to provide protection in the next couple of weeks,\" Mr Burton said on Sunday (Nov 28) on the BBC's Andrew Marr Show.</p><p><blockquote>伯顿周日（11 月 28 日）在 BBC 安德鲁·马尔秀节目中表示：“我们应该了解当前疫苗在未来几周内提供保护的能力。”</blockquote></p><p> \"If we have to make a brand new vaccine, I think that's going to be early 2022 before that's really going to be available in large quantities,\" he said.</p><p><blockquote>“如果我们必须制造一种全新的疫苗，我认为要到 2022 年初才能真正大量上市，”他说。</blockquote></p><p> \"The remarkable thing about the mRNA vaccines, the Moderna platform, is that we can move very fast,\" he added.</p><p><blockquote>“mRNA 疫苗（Moderna 平台）的非凡之处在于我们可以非常快速地移动，”他补充道。</blockquote></p><p> The Cambridge, Massachusetts-based biotech company mobilised \"hundreds\" of staff early last&nbsp;Thursday, Thanksgiving Day in the United States, after news of the Omicron variant spread.</p><p><blockquote>上周四美国感恩节早些时候，在奥密克戎变种病毒的消息传开后，这家总部位于马萨诸塞州剑桥的生物技术公司动员了“数百名”员工。</blockquote></p><p> Protection should still exist, depending on how long ago a person was vaccinated, and for now the best advice is to take one of the current Covid-19 vaccines, Mr Burton said.</p><p><blockquote>伯顿先生说，保护应该仍然存在，这取决于一个人接种疫苗的时间，目前最好的建议是接种当前的 Covid-19 疫苗之一。</blockquote></p><p> \"If people are on the fence, and you haven't been vaccinated, get vaccinated,\" he said. \"This is a dangerous-looking virus, but I think we have many tools in our armamentarium now to fight it.\"</p><p><blockquote>“如果人们持观望态度，而你还没有接种疫苗，那就接种疫苗，”他说。“这是一种看起来很危险的病毒，但我认为我们现在的武器库中有很多工具可以对抗它。”</blockquote></p><p> The emergence of the Omicron strain has seen countries rush to clamp down on travel from southern Africa.</p><p><blockquote>奥密克戎病毒的出现导致各国急于限制来自南部非洲的旅行。</blockquote></p><p> Fears that it could exacerbate a winter Covid-19 surge in the northern hemisphere and undermine a global economic recovery sent a wave of risk aversion across global markets last&nbsp;Friday that continued on Sunday when the Middle East opened for the week.</p><p><blockquote>上周五，由于担心这可能会加剧北半球冬季新冠肺炎疫情激增并破坏全球经济复苏，全球市场掀起了一波避险情绪，这种情绪在周日中东开盘时仍在继续。</blockquote></p><p> Moderna said in a release on Friday that it was working rapidly to test the current vaccine against the Omicron variant, and studying two booster candidates.</p><p><blockquote>Moderna在周五的一份新闻稿中表示，它正在快速测试当前针对奥密克戎变种的疫苗，并研究两种候选加强剂。</blockquote></p><p> \"Since early 2021, Moderna has advanced a comprehensive strategy to anticipate new variants of concern,\" the company said. \"The company has repeatedly demonstrated the ability to advance new candidates to clinical testing in 60 to 90 days.\"</p><p><blockquote>该公司表示：“自 2021 年初以来，Moderna 已推进一项全面战略，以预测令人担忧的新变种。”“该公司已多次证明有能力在 60 至 90 天内将新候选药物推进临床试验。”</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106015985","content_text":"Moderna stock surged 8% in premarket trading as it said new covid-19 vaccine for Omicron might be ready in early 2022.\n\nModerna chief medical officer Paul Burton said he suspects the new Omicron coronavirus variant may elude current vaccines, and if so, a reformulated shot could be available early in the new year.\n\"We should know about the ability of the current vaccine to provide protection in the next couple of weeks,\" Mr Burton said on Sunday (Nov 28) on the BBC's Andrew Marr Show.\n\"If we have to make a brand new vaccine, I think that's going to be early 2022 before that's really going to be available in large quantities,\" he said.\n\"The remarkable thing about the mRNA vaccines, the Moderna platform, is that we can move very fast,\" he added.\nThe Cambridge, Massachusetts-based biotech company mobilised \"hundreds\" of staff early last Thursday, Thanksgiving Day in the United States, after news of the Omicron variant spread.\nProtection should still exist, depending on how long ago a person was vaccinated, and for now the best advice is to take one of the current Covid-19 vaccines, Mr Burton said.\n\"If people are on the fence, and you haven't been vaccinated, get vaccinated,\" he said. \"This is a dangerous-looking virus, but I think we have many tools in our armamentarium now to fight it.\"\nThe emergence of the Omicron strain has seen countries rush to clamp down on travel from southern Africa.\nFears that it could exacerbate a winter Covid-19 surge in the northern hemisphere and undermine a global economic recovery sent a wave of risk aversion across global markets last Friday that continued on Sunday when the Middle East opened for the week.\nModerna said in a release on Friday that it was working rapidly to test the current vaccine against the Omicron variant, and studying two booster candidates.\n\"Since early 2021, Moderna has advanced a comprehensive strategy to anticipate new variants of concern,\" the company said. \"The company has repeatedly demonstrated the ability to advance new candidates to clinical testing in 60 to 90 days.\"","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1164,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877248717,"gmtCreate":1637938674890,"gmtModify":1637938674890,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089880892731870","idStr":"4089880892731870"},"themes":[],"title":"","htmlText":"To the moon!&nbsp;<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>[财迷]&nbsp;[财迷]&nbsp;","listText":"To the moon!&nbsp;<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>[财迷]&nbsp;[财迷]&nbsp;","text":"To the moon! $Moderna, Inc.(MRNA)$[财迷] [财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877248717","repostId":"1125886564","repostType":2,"repost":{"id":"1125886564","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637938179,"share":"https://www.laohunote.com/m/news/1125886564?lang=zh_CN&edition=full","pubTime":"2021-11-26 22:49","market":"us","language":"en","title":"Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23%.<blockquote>疫苗股早盘继续上涨，Moderna股价飙升超过23%。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1125886564","media":"Tiger Newspress","summary":"Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23% and BioNTech ","content":"<p>Vaccine&nbsp;stocks&nbsp;continued&nbsp;to&nbsp;rise&nbsp;in&nbsp;early&nbsp;trading,&nbsp;Moderna&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;23%&nbsp;and&nbsp;BioNTech&nbsp;jumped&nbsp;nearly&nbsp;19%.<img src=\"https://static.tigerbbs.com/2e9f40662925ec57d0176cf5f1e36df4\" tg-width=\"876\" tg-height=\"613\" referrerpolicy=\"no-referrer\">Germany's BioNTech &nbsp;said it is studying the effectiveness of its COVID-19 vaccine against the new B.1.1.529 variant detected in South Africa - The Economic Times.</p><p><blockquote>疫苗股早盘继续上涨，Moderna股价飙升超过23%，BioNTech大涨近19%。德国 BioNTech 表示，正在研究其新冠肺炎疫苗对南非检测到的新 B.1.1.529 变种的有效性 - 经济时报。</blockquote></p><p> \"We expect more data from the laboratory tests in two weeks at the latest. These data will provide more information about whether B.1.1.529 could be an escape variant that may require an adjustment of our vaccine if the variant spreads globally,\" a BioNTech spokesperson said.</p><p><blockquote>BioNTech 发言人表示：“我们预计最迟两周内将获得更多来自实验室测试的数据。这些数据将提供有关 B.1.1.529 是否可能是逃逸变种的更多信息，如果该变种在全球传播，可能需要调整我们的疫苗。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23%.<blockquote>疫苗股早盘继续上涨，Moderna股价飙升超过23%。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine stocks continued to rise in early trading, Moderna shares surged more than 23%.<blockquote>疫苗股早盘继续上涨，Moderna股价飙升超过23%。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-26 22:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Vaccine&nbsp;stocks&nbsp;continued&nbsp;to&nbsp;rise&nbsp;in&nbsp;early&nbsp;trading,&nbsp;Moderna&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;23%&nbsp;and&nbsp;BioNTech&nbsp;jumped&nbsp;nearly&nbsp;19%.<img src=\"https://static.tigerbbs.com/2e9f40662925ec57d0176cf5f1e36df4\" tg-width=\"876\" tg-height=\"613\" referrerpolicy=\"no-referrer\">Germany's BioNTech &nbsp;said it is studying the effectiveness of its COVID-19 vaccine against the new B.1.1.529 variant detected in South Africa - The Economic Times.</p><p><blockquote>疫苗股早盘继续上涨，Moderna股价飙升超过23%，BioNTech大涨近19%。德国 BioNTech 表示，正在研究其新冠肺炎疫苗对南非检测到的新 B.1.1.529 变种的有效性 - 经济时报。</blockquote></p><p> \"We expect more data from the laboratory tests in two weeks at the latest. These data will provide more information about whether B.1.1.529 could be an escape variant that may require an adjustment of our vaccine if the variant spreads globally,\" a BioNTech spokesperson said.</p><p><blockquote>BioNTech 发言人表示：“我们预计最迟两周内将获得更多来自实验室测试的数据。这些数据将提供有关 B.1.1.529 是否可能是逃逸变种的更多信息，如果该变种在全球传播，可能需要调整我们的疫苗。”</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125886564","content_text":"Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23% and BioNTech jumped nearly 19%.Germany's BioNTech  said it is studying the effectiveness of its COVID-19 vaccine against the new B.1.1.529 variant detected in South Africa - The Economic Times.\n\"We expect more data from the laboratory tests in two weeks at the latest. These data will provide more information about whether B.1.1.529 could be an escape variant that may require an adjustment of our vaccine if the variant spreads globally,\" a BioNTech spokesperson said.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1296,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874886130,"gmtCreate":1637757497676,"gmtModify":1637760515797,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089880892731870","idStr":"4089880892731870"},"themes":[],"title":"","htmlText":"Buy the dip and let's wait for the climb.&nbsp;[财迷]&nbsp;<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>https://www.businesstimes.com.sg/companies-markets/brokers-take-dbs-raises-sea-tp-to-us402-on-higher-valuation-from-e-commerce","listText":"Buy the dip and let's wait for the climb.&nbsp;[财迷]&nbsp;<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>https://www.businesstimes.com.sg/companies-markets/brokers-take-dbs-raises-sea-tp-to-us402-on-higher-valuation-from-e-commerce","text":"Buy the dip and let's wait for the climb. [财迷] $Sea Ltd(SE)$https://www.businesstimes.com.sg/companies-markets/brokers-take-dbs-raises-sea-tp-to-us402-on-higher-valuation-from-e-commerce","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874886130","isVote":1,"tweetType":1,"viewCount":1360,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872838004,"gmtCreate":1637469763226,"gmtModify":1637469763226,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089880892731870","idStr":"4089880892731870"},"themes":[],"title":"","htmlText":"more to grow&nbsp;[财迷]&nbsp;","listText":"more to grow&nbsp;[财迷]&nbsp;","text":"more to grow [财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/872838004","repostId":"1129693973","repostType":4,"repost":{"id":"1129693973","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637332940,"share":"https://www.laohunote.com/m/news/1129693973?lang=zh_CN&edition=full","pubTime":"2021-11-19 22:42","market":"us","language":"en","title":"Moderna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading<blockquote>Moderna 上涨超过 8%，辉瑞和 BioNTech SE 在早盘交易中上涨约 2%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1129693973","media":"Tiger Newspress","summary":"Moderna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading.Pfizer(PFE.US)","content":"<p>Moderna jumped over&nbsp;8% while Pfizer and BioNTech SE rose around 2% in morning trading.<img src=\"https://static.tigerbbs.com/1788750b32795d8eb3fbb1f2b7eb08a3\" tg-width=\"773\" tg-height=\"565\" referrerpolicy=\"no-referrer\">Pfizer(PFE.US) plans to apply to the European Union for authorization of its COVID-19 drug Paxlovid today.In addition, the report pointed out that German Health Minister Jens Spahn planned to purchase Paxlovid.</p><p><blockquote>Moderna 上涨超过 8%，而辉瑞和 BioNTech SE 在早盘交易中上涨约 2%。辉瑞（PFE.US）计划于今日向欧盟申请其新冠肺炎药物Paxlovid的授权。此外，报道指出，德国卫生部长延斯·施潘计划采购Paxlovid。</blockquote></p><p> The report quoted a spokesman for the German Ministry of Health as saying: \"The Ministry of Health is in contact with Pfizer on the possible purchase of COVID-19 drug Paxlovid.\"</p><p><blockquote>报道援引德国卫生部发言人的话称：“卫生部正在与辉瑞公司就可能购买新冠肺炎药物Paxlovid一事进行接触。”</blockquote></p><p> Moreover，Moderna, Inc.&nbsp;today announced that the&nbsp;U.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p><p><blockquote>此外，Moderna, Inc. 今天宣布美国。美国食品药品监督管理局 (FDA) 已将 50 µg 剂量水平的 Moderna COVID-19 疫苗加强剂量的紧急使用授权扩大到所有 18 岁及以上成年人。这种加强剂可用于所有18岁及以上已完成任何其他授权或批准的新冠肺炎疫苗初次接种的个人。</blockquote></p><p> “This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p><p><blockquote>“Moderna 首席执行官斯特凡-班塞尔（Stéphane Bancel）说：”这项紧急使用授权正值我们进入冬季的关键时刻，全国范围内 COVID-19 病例数和住院人数不断增加。“我们感谢美国食品和药物管理局的审查，并对强有力的临床证据充满信心，即 50 µg 加强剂量的 mRNA-1273 可诱导针对 COVID-19 的强烈免疫反应。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading<blockquote>Moderna 上涨超过 8%，辉瑞和 BioNTech SE 在早盘交易中上涨约 2%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading<blockquote>Moderna 上涨超过 8%，辉瑞和 BioNTech SE 在早盘交易中上涨约 2%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-19 22:42</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Moderna jumped over&nbsp;8% while Pfizer and BioNTech SE rose around 2% in morning trading.<img src=\"https://static.tigerbbs.com/1788750b32795d8eb3fbb1f2b7eb08a3\" tg-width=\"773\" tg-height=\"565\" referrerpolicy=\"no-referrer\">Pfizer(PFE.US) plans to apply to the European Union for authorization of its COVID-19 drug Paxlovid today.In addition, the report pointed out that German Health Minister Jens Spahn planned to purchase Paxlovid.</p><p><blockquote>Moderna 上涨超过 8%，而辉瑞和 BioNTech SE 在早盘交易中上涨约 2%。辉瑞（PFE.US）计划于今日向欧盟申请其新冠肺炎药物Paxlovid的授权。此外，报道指出，德国卫生部长延斯·施潘计划采购Paxlovid。</blockquote></p><p> The report quoted a spokesman for the German Ministry of Health as saying: \"The Ministry of Health is in contact with Pfizer on the possible purchase of COVID-19 drug Paxlovid.\"</p><p><blockquote>报道援引德国卫生部发言人的话称：“卫生部正在与辉瑞公司就可能购买新冠肺炎药物Paxlovid一事进行接触。”</blockquote></p><p> Moreover，Moderna, Inc.&nbsp;today announced that the&nbsp;U.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p><p><blockquote>此外，Moderna, Inc. 今天宣布美国。美国食品药品监督管理局 (FDA) 已将 50 µg 剂量水平的 Moderna COVID-19 疫苗加强剂量的紧急使用授权扩大到所有 18 岁及以上成年人。这种加强剂可用于所有18岁及以上已完成任何其他授权或批准的新冠肺炎疫苗初次接种的个人。</blockquote></p><p> “This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p><p><blockquote>“Moderna 首席执行官斯特凡-班塞尔（Stéphane Bancel）说：”这项紧急使用授权正值我们进入冬季的关键时刻，全国范围内 COVID-19 病例数和住院人数不断增加。“我们感谢美国食品和药物管理局的审查，并对强有力的临床证据充满信心，即 50 µg 加强剂量的 mRNA-1273 可诱导针对 COVID-19 的强烈免疫反应。”</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129693973","content_text":"Moderna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading.Pfizer(PFE.US) plans to apply to the European Union for authorization of its COVID-19 drug Paxlovid today.In addition, the report pointed out that German Health Minister Jens Spahn planned to purchase Paxlovid.\nThe report quoted a spokesman for the German Ministry of Health as saying: \"The Ministry of Health is in contact with Pfizer on the possible purchase of COVID-19 drug Paxlovid.\"\nMoreover，Moderna, Inc. today announced that the U.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.\n“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”","news_type":1,"symbols_score_info":{"PFE":0.9,"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1847,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876591196,"gmtCreate":1637329144369,"gmtModify":1637329144469,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089880892731870","idStr":"4089880892731870"},"themes":[],"title":"","htmlText":"about time! so many different studies have showed increased protection with&nbsp;<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>","listText":"about time! so many different studies have showed increased protection with&nbsp;<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>","text":"about time! so many different studies have showed increased protection with $Moderna, Inc.(MRNA)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876591196","repostId":"1138047553","repostType":2,"repost":{"id":"1138047553","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637327403,"share":"https://www.laohunote.com/m/news/1138047553?lang=zh_CN&edition=full","pubTime":"2021-11-19 21:10","market":"us","language":"en","title":"Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older<blockquote>Moderna 宣布 FDA 批准在美国为 18 岁及以上成年人接种加强剂量的 COVID-19 疫苗</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1138047553","media":"Tiger Newspress","summary":"Moderna stock surged 4% in premarket trading after announcing FDA authorization of booster dose of C","content":"<p>Moderna stock surged 4% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p><p><blockquote>Moderna 宣布 FDA 批准在美国为 18 岁及以上成年人接种加强剂量 COVID-19 疫苗后，其股价在盘前交易中飙升 4%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b8db683899273d344e819a53f4b3366b\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Moderna, Inc.&nbsp;today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p><p><blockquote>Moderna, Inc. 今天宣布，美国。美国食品药品监督管理局 (FDA) 已将 50 µg 剂量水平的 Moderna COVID-19 疫苗加强剂量的紧急使用授权扩大到所有 18 岁及以上成年人。这种加强剂可用于所有18岁及以上已完成任何其他授权或批准的新冠肺炎疫苗初次接种的个人。</blockquote></p><p> “This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p><p><blockquote>“Moderna 首席执行官斯特凡-班塞尔（Stéphane Bancel）说：”这项紧急使用授权正值我们进入冬季的关键时刻，全国范围内 COVID-19 病例数和住院人数不断增加。“我们感谢美国食品和药物管理局的审查，并对强有力的临床证据充满信心，即 50 µg 加强剂量的 mRNA-1273 可诱导针对 COVID-19 的强烈免疫反应。”</blockquote></p><p> The booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.</p><p><blockquote>加强剂量应在完成任何初级系列新冠肺炎疫苗接种后至少六个月施用。10 月 20 日，FDA 授权紧急使用 50 µg 剂量水平的 Moderna COVID-19 疫苗加强剂量，用于 65 岁及以上的人群以及 18 至 64 岁的成年人，他们处于严重 COVID-19 的高风险；以及经常在机构或职业中接触新型冠状病毒的18至64岁人群。在许多国际市场上，Moderna新冠肺炎加强疫苗被授权用于18岁及以上的成年人，无论职业风险因素如何。在此之前，100 µg mRNA 1273 第三剂已被批准用于免疫功能低下的个体。</blockquote></p><p> The FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.</p><p><blockquote>FDA 基于该公司共享的所有科学证据，包括 mRNA-1273 2 期临床研究的数据分析，该研究经过修订，在第二次给药后 6-8 个月向感兴趣的参与者提供 50 µg 剂量水平的 mRNA-1273 加强剂量（n=344）。中和抗体滴度在加强之前已经减弱，特别是针对关注的变体，在大约6个月时。值得注意的是，50 µg 剂量水平的 mRNA-1273 加强剂量使中和滴度显著高于 3 期基准。加强剂量后的安全性特征与先前观察到的mRNA-1273剂量2相似。</blockquote></p><p> As a next step, theU.S. Centers for Disease Controland Prevention’s (CDC)&nbsp;Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.</p><p><blockquote>下一步，美国。美国疾病控制中心（CDC）免疫实践咨询委员会（ACIP）将召开会议，讨论向美国人推广 COVID-19 加强剂的潜在建议。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older<blockquote>Moderna 宣布 FDA 批准在美国为 18 岁及以上成年人接种加强剂量的 COVID-19 疫苗</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older<blockquote>Moderna 宣布 FDA 批准在美国为 18 岁及以上成年人接种加强剂量的 COVID-19 疫苗</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-19 21:10</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Moderna stock surged 4% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p><p><blockquote>Moderna 宣布 FDA 批准在美国为 18 岁及以上成年人接种加强剂量 COVID-19 疫苗后，其股价在盘前交易中飙升 4%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b8db683899273d344e819a53f4b3366b\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Moderna, Inc.&nbsp;today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p><p><blockquote>Moderna, Inc. 今天宣布，美国。美国食品药品监督管理局 (FDA) 已将 50 µg 剂量水平的 Moderna COVID-19 疫苗加强剂量的紧急使用授权扩大到所有 18 岁及以上成年人。这种加强剂可用于所有18岁及以上已完成任何其他授权或批准的新冠肺炎疫苗初次接种的个人。</blockquote></p><p> “This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p><p><blockquote>“Moderna 首席执行官斯特凡-班塞尔（Stéphane Bancel）说：”这项紧急使用授权正值我们进入冬季的关键时刻，全国范围内 COVID-19 病例数和住院人数不断增加。“我们感谢美国食品和药物管理局的审查，并对强有力的临床证据充满信心，即 50 µg 加强剂量的 mRNA-1273 可诱导针对 COVID-19 的强烈免疫反应。”</blockquote></p><p> The booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.</p><p><blockquote>加强剂量应在完成任何初级系列新冠肺炎疫苗接种后至少六个月施用。10 月 20 日，FDA 授权紧急使用 50 µg 剂量水平的 Moderna COVID-19 疫苗加强剂量，用于 65 岁及以上的人群以及 18 至 64 岁的成年人，他们处于严重 COVID-19 的高风险；以及经常在机构或职业中接触新型冠状病毒的18至64岁人群。在许多国际市场上，Moderna新冠肺炎加强疫苗被授权用于18岁及以上的成年人，无论职业风险因素如何。在此之前，100 µg mRNA 1273 第三剂已被批准用于免疫功能低下的个体。</blockquote></p><p> The FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.</p><p><blockquote>FDA 基于该公司共享的所有科学证据，包括 mRNA-1273 2 期临床研究的数据分析，该研究经过修订，在第二次给药后 6-8 个月向感兴趣的参与者提供 50 µg 剂量水平的 mRNA-1273 加强剂量（n=344）。中和抗体滴度在加强之前已经减弱，特别是针对关注的变体，在大约6个月时。值得注意的是，50 µg 剂量水平的 mRNA-1273 加强剂量使中和滴度显著高于 3 期基准。加强剂量后的安全性特征与先前观察到的mRNA-1273剂量2相似。</blockquote></p><p> As a next step, theU.S. Centers for Disease Controland Prevention’s (CDC)&nbsp;Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.</p><p><blockquote>下一步，美国。美国疾病控制中心（CDC）免疫实践咨询委员会（ACIP）将召开会议，讨论向美国人推广 COVID-19 加强剂的潜在建议。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138047553","content_text":"Moderna stock surged 4% in premarket trading after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.\n\nModerna, Inc. today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.\n“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”\nThe booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.\nThe FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.\nAs a next step, theU.S. Centers for Disease Controland Prevention’s (CDC) Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1203,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":833712317,"gmtCreate":1629262600439,"gmtModify":1631884077863,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089880892731870","idStr":"4089880892731870"},"themes":[],"title":"","htmlText":"Honestly in my humble opinion, with the strong and rapid spread of the delta variant, there's going to be an increase in demand for vaccine jabs and booster jabs - making&nbsp;<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>a very much keep-worthy stock vs. dumping it.&nbsp;","listText":"Honestly in my humble opinion, with the strong and rapid spread of the delta variant, there's going to be an increase in demand for vaccine jabs and booster jabs - making&nbsp;<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>a very much keep-worthy stock vs. dumping it.&nbsp;","text":"Honestly in my humble opinion, with the strong and rapid spread of the delta variant, there's going to be an increase in demand for vaccine jabs and booster jabs - making $Moderna, Inc.(MRNA)$a very much keep-worthy stock vs. dumping it.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":7,"repostSize":0,"link":"https://laohu8.com/post/833712317","isVote":1,"tweetType":1,"viewCount":990,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000221","authorId":"9000000000000221","name":"搞钱树","avatar":"https://static.tigerbbs.com/82edc4968feb7c0c481f5ad38d9a498b","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"9000000000000221","idStr":"9000000000000221"},"content":"一直比较关注$莫德纳公司(MRNA)$ ，只不过以前太痴情中概股，现在改变了，只不过还能买吗？","text":"一直比较关注$莫德纳公司(MRNA)$ ，只不过以前太痴情中概股，现在改变了，只不过还能买吗？","html":"一直比较关注$莫德纳公司(MRNA)$ ，只不过以前太痴情中概股，现在改变了，只不过还能买吗？"},{"author":{"id":"9000000000000159","authorId":"9000000000000159","name":"宝宝金水_","avatar":"https://static.tigerbbs.com/3277b62086966882a8b4e45d9f8b88bb","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"9000000000000159","idStr":"9000000000000159"},"content":"看样子昨天确实是买点呀，今天看看要是有合适的价格也买一丢丢。","text":"看样子昨天确实是买点呀，今天看看要是有合适的价格也买一丢丢。","html":"看样子昨天确实是买点呀，今天看看要是有合适的价格也买一丢丢。"}],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":833712317,"gmtCreate":1629262600439,"gmtModify":1631884077863,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"title":"","htmlText":"Honestly in my humble opinion, with the strong and rapid spread of the delta variant, there's going to be an increase in demand for vaccine jabs and booster jabs - making&nbsp;<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>a very much keep-worthy stock vs. dumping it.&nbsp;","listText":"Honestly in my humble opinion, with the strong and rapid spread of the delta variant, there's going to be an increase in demand for vaccine jabs and booster jabs - making&nbsp;<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>a very much keep-worthy stock vs. dumping it.&nbsp;","text":"Honestly in my humble opinion, with the strong and rapid spread of the delta variant, there's going to be an increase in demand for vaccine jabs and booster jabs - making $Moderna, Inc.(MRNA)$a very much keep-worthy stock vs. dumping it.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":7,"repostSize":0,"link":"https://laohu8.com/post/833712317","isVote":1,"tweetType":1,"viewCount":990,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000221","authorId":"9000000000000221","name":"搞钱树","avatar":"https://static.tigerbbs.com/82edc4968feb7c0c481f5ad38d9a498b","crmLevel":1,"crmLevelSwitch":0,"idStr":"9000000000000221","authorIdStr":"9000000000000221"},"content":"一直比较关注$莫德纳公司(MRNA)$ ，只不过以前太痴情中概股，现在改变了，只不过还能买吗？","text":"一直比较关注$莫德纳公司(MRNA)$ ，只不过以前太痴情中概股，现在改变了，只不过还能买吗？","html":"一直比较关注$莫德纳公司(MRNA)$ ，只不过以前太痴情中概股，现在改变了，只不过还能买吗？"},{"author":{"id":"9000000000000159","authorId":"9000000000000159","name":"宝宝金水_","avatar":"https://static.tigerbbs.com/3277b62086966882a8b4e45d9f8b88bb","crmLevel":1,"crmLevelSwitch":0,"idStr":"9000000000000159","authorIdStr":"9000000000000159"},"content":"看样子昨天确实是买点呀，今天看看要是有合适的价格也买一丢丢。","text":"看样子昨天确实是买点呀，今天看看要是有合适的价格也买一丢丢。","html":"看样子昨天确实是买点呀，今天看看要是有合适的价格也买一丢丢。"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":876591196,"gmtCreate":1637329144369,"gmtModify":1637329144469,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"title":"","htmlText":"about time! so many different studies have showed increased protection with&nbsp;<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>","listText":"about time! so many different studies have showed increased protection with&nbsp;<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>","text":"about time! so many different studies have showed increased protection with $Moderna, Inc.(MRNA)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876591196","repostId":"1138047553","repostType":2,"repost":{"id":"1138047553","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637327403,"share":"https://www.laohunote.com/m/news/1138047553?lang=zh_CN&edition=full","pubTime":"2021-11-19 21:10","market":"us","language":"en","title":"Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older<blockquote>Moderna 宣布 FDA 批准在美国为 18 岁及以上成年人接种加强剂量的 COVID-19 疫苗</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1138047553","media":"Tiger Newspress","summary":"Moderna stock surged 4% in premarket trading after announcing FDA authorization of booster dose of C","content":"<p>Moderna stock surged 4% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p><p><blockquote>Moderna 宣布 FDA 批准在美国为 18 岁及以上成年人接种加强剂量 COVID-19 疫苗后，其股价在盘前交易中飙升 4%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b8db683899273d344e819a53f4b3366b\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Moderna, Inc.&nbsp;today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p><p><blockquote>Moderna, Inc. 今天宣布，美国。美国食品药品监督管理局 (FDA) 已将 50 µg 剂量水平的 Moderna COVID-19 疫苗加强剂量的紧急使用授权扩大到所有 18 岁及以上成年人。这种加强剂可用于所有18岁及以上已完成任何其他授权或批准的新冠肺炎疫苗初次接种的个人。</blockquote></p><p> “This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p><p><blockquote>“Moderna 首席执行官斯特凡-班塞尔（Stéphane Bancel）说：”这项紧急使用授权正值我们进入冬季的关键时刻，全国范围内 COVID-19 病例数和住院人数不断增加。“我们感谢美国食品和药物管理局的审查，并对强有力的临床证据充满信心，即 50 µg 加强剂量的 mRNA-1273 可诱导针对 COVID-19 的强烈免疫反应。”</blockquote></p><p> The booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.</p><p><blockquote>加强剂量应在完成任何初级系列新冠肺炎疫苗接种后至少六个月施用。10 月 20 日，FDA 授权紧急使用 50 µg 剂量水平的 Moderna COVID-19 疫苗加强剂量，用于 65 岁及以上的人群以及 18 至 64 岁的成年人，他们处于严重 COVID-19 的高风险；以及经常在机构或职业中接触新型冠状病毒的18至64岁人群。在许多国际市场上，Moderna新冠肺炎加强疫苗被授权用于18岁及以上的成年人，无论职业风险因素如何。在此之前，100 µg mRNA 1273 第三剂已被批准用于免疫功能低下的个体。</blockquote></p><p> The FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.</p><p><blockquote>FDA 基于该公司共享的所有科学证据，包括 mRNA-1273 2 期临床研究的数据分析，该研究经过修订，在第二次给药后 6-8 个月向感兴趣的参与者提供 50 µg 剂量水平的 mRNA-1273 加强剂量（n=344）。中和抗体滴度在加强之前已经减弱，特别是针对关注的变体，在大约6个月时。值得注意的是，50 µg 剂量水平的 mRNA-1273 加强剂量使中和滴度显著高于 3 期基准。加强剂量后的安全性特征与先前观察到的mRNA-1273剂量2相似。</blockquote></p><p> As a next step, theU.S. Centers for Disease Controland Prevention’s (CDC)&nbsp;Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.</p><p><blockquote>下一步，美国。美国疾病控制中心（CDC）免疫实践咨询委员会（ACIP）将召开会议，讨论向美国人推广 COVID-19 加强剂的潜在建议。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older<blockquote>Moderna 宣布 FDA 批准在美国为 18 岁及以上成年人接种加强剂量的 COVID-19 疫苗</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older<blockquote>Moderna 宣布 FDA 批准在美国为 18 岁及以上成年人接种加强剂量的 COVID-19 疫苗</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-19 21:10</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Moderna stock surged 4% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p><p><blockquote>Moderna 宣布 FDA 批准在美国为 18 岁及以上成年人接种加强剂量 COVID-19 疫苗后，其股价在盘前交易中飙升 4%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b8db683899273d344e819a53f4b3366b\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Moderna, Inc.&nbsp;today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p><p><blockquote>Moderna, Inc. 今天宣布，美国。美国食品药品监督管理局 (FDA) 已将 50 µg 剂量水平的 Moderna COVID-19 疫苗加强剂量的紧急使用授权扩大到所有 18 岁及以上成年人。这种加强剂可用于所有18岁及以上已完成任何其他授权或批准的新冠肺炎疫苗初次接种的个人。</blockquote></p><p> “This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p><p><blockquote>“Moderna 首席执行官斯特凡-班塞尔（Stéphane Bancel）说：”这项紧急使用授权正值我们进入冬季的关键时刻，全国范围内 COVID-19 病例数和住院人数不断增加。“我们感谢美国食品和药物管理局的审查，并对强有力的临床证据充满信心，即 50 µg 加强剂量的 mRNA-1273 可诱导针对 COVID-19 的强烈免疫反应。”</blockquote></p><p> The booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.</p><p><blockquote>加强剂量应在完成任何初级系列新冠肺炎疫苗接种后至少六个月施用。10 月 20 日，FDA 授权紧急使用 50 µg 剂量水平的 Moderna COVID-19 疫苗加强剂量，用于 65 岁及以上的人群以及 18 至 64 岁的成年人，他们处于严重 COVID-19 的高风险；以及经常在机构或职业中接触新型冠状病毒的18至64岁人群。在许多国际市场上，Moderna新冠肺炎加强疫苗被授权用于18岁及以上的成年人，无论职业风险因素如何。在此之前，100 µg mRNA 1273 第三剂已被批准用于免疫功能低下的个体。</blockquote></p><p> The FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.</p><p><blockquote>FDA 基于该公司共享的所有科学证据，包括 mRNA-1273 2 期临床研究的数据分析，该研究经过修订，在第二次给药后 6-8 个月向感兴趣的参与者提供 50 µg 剂量水平的 mRNA-1273 加强剂量（n=344）。中和抗体滴度在加强之前已经减弱，特别是针对关注的变体，在大约6个月时。值得注意的是，50 µg 剂量水平的 mRNA-1273 加强剂量使中和滴度显著高于 3 期基准。加强剂量后的安全性特征与先前观察到的mRNA-1273剂量2相似。</blockquote></p><p> As a next step, theU.S. Centers for Disease Controland Prevention’s (CDC)&nbsp;Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.</p><p><blockquote>下一步，美国。美国疾病控制中心（CDC）免疫实践咨询委员会（ACIP）将召开会议，讨论向美国人推广 COVID-19 加强剂的潜在建议。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138047553","content_text":"Moderna stock surged 4% in premarket trading after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.\n\nModerna, Inc. today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.\n“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”\nThe booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.\nThe FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.\nAs a next step, theU.S. Centers for Disease Controland Prevention’s (CDC) Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1203,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602132570,"gmtCreate":1638979550717,"gmtModify":1638979550717,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"title":"","htmlText":"to the moon!&nbsp;[Cool]&nbsp;[Cool]&nbsp;","listText":"to the moon!&nbsp;[Cool]&nbsp;[Cool]&nbsp;","text":"to the moon! [Cool] [Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/602132570","repostId":"1161444269","repostType":4,"repost":{"id":"1161444269","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638977215,"share":"https://www.laohunote.com/m/news/1161444269?lang=zh_CN&edition=full","pubTime":"2021-12-08 23:26","market":"us","language":"en","title":"Apple shares rose nearly 2% to a new high<blockquote>苹果股价上涨近2%创新高</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1161444269","media":"Tiger Newspress","summary":"Apple shares rose nearly 2% to a new high in morning trading.","content":"<p>Apple shares rose nearly 2% to a new high&nbsp;in morning trading.</p><p><blockquote>苹果股价在早盘交易中上涨近2%，创下新高。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/9a9f5fdc1cb0a898675c515a39de7611\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple shares rose nearly 2% to a new high<blockquote>苹果股价上涨近2%创新高</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple shares rose nearly 2% to a new high<blockquote>苹果股价上涨近2%创新高</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-08 23:26</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Apple shares rose nearly 2% to a new high&nbsp;in morning trading.</p><p><blockquote>苹果股价在早盘交易中上涨近2%，创下新高。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/9a9f5fdc1cb0a898675c515a39de7611\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161444269","content_text":"Apple shares rose nearly 2% to a new high in morning trading.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":4629,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603132509,"gmtCreate":1638372243529,"gmtModify":1638372243668,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"title":"","htmlText":"A good time to buy in&nbsp;<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>[Cool]&nbsp;","listText":"A good time to buy in&nbsp;<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>[Cool]&nbsp;","text":"A good time to buy in $Sea Ltd(SE)$[Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603132509","repostId":"2186310769","repostType":2,"isVote":1,"tweetType":1,"viewCount":3887,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877248717,"gmtCreate":1637938674890,"gmtModify":1637938674890,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"title":"","htmlText":"To the moon!&nbsp;<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>[财迷]&nbsp;[财迷]&nbsp;","listText":"To the moon!&nbsp;<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>[财迷]&nbsp;[财迷]&nbsp;","text":"To the moon! $Moderna, Inc.(MRNA)$[财迷] [财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877248717","repostId":"1125886564","repostType":2,"repost":{"id":"1125886564","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637938179,"share":"https://www.laohunote.com/m/news/1125886564?lang=zh_CN&edition=full","pubTime":"2021-11-26 22:49","market":"us","language":"en","title":"Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23%.<blockquote>疫苗股早盘继续上涨，Moderna股价飙升超过23%。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1125886564","media":"Tiger Newspress","summary":"Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23% and BioNTech ","content":"<p>Vaccine&nbsp;stocks&nbsp;continued&nbsp;to&nbsp;rise&nbsp;in&nbsp;early&nbsp;trading,&nbsp;Moderna&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;23%&nbsp;and&nbsp;BioNTech&nbsp;jumped&nbsp;nearly&nbsp;19%.<img src=\"https://static.tigerbbs.com/2e9f40662925ec57d0176cf5f1e36df4\" tg-width=\"876\" tg-height=\"613\" referrerpolicy=\"no-referrer\">Germany's BioNTech &nbsp;said it is studying the effectiveness of its COVID-19 vaccine against the new B.1.1.529 variant detected in South Africa - The Economic Times.</p><p><blockquote>疫苗股早盘继续上涨，Moderna股价飙升超过23%，BioNTech大涨近19%。德国 BioNTech 表示，正在研究其新冠肺炎疫苗对南非检测到的新 B.1.1.529 变种的有效性 - 经济时报。</blockquote></p><p> \"We expect more data from the laboratory tests in two weeks at the latest. These data will provide more information about whether B.1.1.529 could be an escape variant that may require an adjustment of our vaccine if the variant spreads globally,\" a BioNTech spokesperson said.</p><p><blockquote>BioNTech 发言人表示：“我们预计最迟两周内将获得更多来自实验室测试的数据。这些数据将提供有关 B.1.1.529 是否可能是逃逸变种的更多信息，如果该变种在全球传播，可能需要调整我们的疫苗。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23%.<blockquote>疫苗股早盘继续上涨，Moderna股价飙升超过23%。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine stocks continued to rise in early trading, Moderna shares surged more than 23%.<blockquote>疫苗股早盘继续上涨，Moderna股价飙升超过23%。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-26 22:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Vaccine&nbsp;stocks&nbsp;continued&nbsp;to&nbsp;rise&nbsp;in&nbsp;early&nbsp;trading,&nbsp;Moderna&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;23%&nbsp;and&nbsp;BioNTech&nbsp;jumped&nbsp;nearly&nbsp;19%.<img src=\"https://static.tigerbbs.com/2e9f40662925ec57d0176cf5f1e36df4\" tg-width=\"876\" tg-height=\"613\" referrerpolicy=\"no-referrer\">Germany's BioNTech &nbsp;said it is studying the effectiveness of its COVID-19 vaccine against the new B.1.1.529 variant detected in South Africa - The Economic Times.</p><p><blockquote>疫苗股早盘继续上涨，Moderna股价飙升超过23%，BioNTech大涨近19%。德国 BioNTech 表示，正在研究其新冠肺炎疫苗对南非检测到的新 B.1.1.529 变种的有效性 - 经济时报。</blockquote></p><p> \"We expect more data from the laboratory tests in two weeks at the latest. These data will provide more information about whether B.1.1.529 could be an escape variant that may require an adjustment of our vaccine if the variant spreads globally,\" a BioNTech spokesperson said.</p><p><blockquote>BioNTech 发言人表示：“我们预计最迟两周内将获得更多来自实验室测试的数据。这些数据将提供有关 B.1.1.529 是否可能是逃逸变种的更多信息，如果该变种在全球传播，可能需要调整我们的疫苗。”</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125886564","content_text":"Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23% and BioNTech jumped nearly 19%.Germany's BioNTech  said it is studying the effectiveness of its COVID-19 vaccine against the new B.1.1.529 variant detected in South Africa - The Economic Times.\n\"We expect more data from the laboratory tests in two weeks at the latest. These data will provide more information about whether B.1.1.529 could be an escape variant that may require an adjustment of our vaccine if the variant spreads globally,\" a BioNTech spokesperson said.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1296,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602453657,"gmtCreate":1639060563339,"gmtModify":1639061378393,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"title":"","htmlText":"very insightful article and shed some light on why&nbsp;<a href=\"https://laohu8.com/S/GRAB\">$Grab Holdings(GRAB)$</a>is doing so badly. only wish it came out earlier&nbsp;[Cry]&nbsp;","listText":"very insightful article and shed some light on why&nbsp;<a href=\"https://laohu8.com/S/GRAB\">$Grab Holdings(GRAB)$</a>is doing so badly. only wish it came out earlier&nbsp;[Cry]&nbsp;","text":"very insightful article and shed some light on why $Grab Holdings(GRAB)$is doing so badly. only wish it came out earlier [Cry]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/602453657","repostId":"2190614747","repostType":2,"isVote":1,"tweetType":1,"viewCount":5551,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602468206,"gmtCreate":1639058758922,"gmtModify":1639059675097,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"title":"","htmlText":"wanted to buy the dip but there isn't really a dip with&nbsp;[LOL]&nbsp;","listText":"wanted to buy the dip but there isn't really a dip with&nbsp;[LOL]&nbsp;","text":"wanted to buy the dip but there isn't really a dip with [LOL]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/602468206","repostId":"1129645066","repostType":4,"repost":{"id":"1129645066","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639053071,"share":"https://www.laohunote.com/m/news/1129645066?lang=zh_CN&edition=full","pubTime":"2021-12-09 20:31","market":"us","language":"en","title":"Amazon shares fell slightly by 0.5% in premarket trading<blockquote>亚马逊股价在盘前交易中小幅下跌 0.5%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1129645066","media":"Tiger Newspress","summary":"Amazon shares fell slightly by 0.5% in premarket trading after Italy's antitrust fined Amazon 1.13 b","content":"<p>Amazon shares fell slightly by 0.5% in premarket trading&nbsp;after&nbsp;Italy's antitrust fined Amazon 1.13 bln euros for alleged abuse of market dominance.</p><p><blockquote>在意大利反垄断机构因涉嫌滥用市场支配地位对亚马逊处以 11.3 亿欧元罚款后，亚马逊股价在盘前交易中小幅下跌 0.5%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/1aa0616746882964f5e05a784287edeb\" tg-width=\"850\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Italy's antitrust said on Thursday it had fined e-commerce giant Amazon 1.13 billion euros ($1.28 billion) for alleged abuse of market dominance.</p><p><blockquote>意大利反垄断机构周四表示，因涉嫌滥用市场支配地位，已对电子商务巨头亚马逊处以 11.3 亿欧元（12.8 亿美元）的罚款。</blockquote></p><p> In a statement the watchdog said Amazon had harmed competing operators in the e-commerce logistics service.</p><p><blockquote>该监管机构在一份声明中表示，亚马逊损害了电子商务物流服务领域的竞争运营商。</blockquote></p><p> \"Amazon holds a dominant position in the Italian market for intermediation services on marketplaces, which Amazon leveraged to favour the adoption of its own logistics service - Fulfilment by Amazon (FBA) - by sellers active on Amazon.it to the detriment of the logistics services offered by competing operators, as well as to strengthen its own dominant position,\" it added.</p><p><blockquote>“亚马逊在意大利市场中介服务市场上占据主导地位，亚马逊利用这一点来鼓励活跃在亚马逊上的卖家采用自己的物流服务——亚马逊履行（FBA）。这损害了竞争对手提供的物流服务运营商，以及加强自己的主导地位，”它补充道。</blockquote></p><p> The antitrust said it would impose on Amazon corrective steps that will be subject to review by a monitoring trustee.</p><p><blockquote>该反垄断机构表示，将对亚马逊采取纠正措施，并接受监控受托人的审查。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amazon shares fell slightly by 0.5% in premarket trading<blockquote>亚马逊股价在盘前交易中小幅下跌 0.5%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmazon shares fell slightly by 0.5% in premarket trading<blockquote>亚马逊股价在盘前交易中小幅下跌 0.5%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-09 20:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Amazon shares fell slightly by 0.5% in premarket trading&nbsp;after&nbsp;Italy's antitrust fined Amazon 1.13 bln euros for alleged abuse of market dominance.</p><p><blockquote>在意大利反垄断机构因涉嫌滥用市场支配地位对亚马逊处以 11.3 亿欧元罚款后，亚马逊股价在盘前交易中小幅下跌 0.5%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/1aa0616746882964f5e05a784287edeb\" tg-width=\"850\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Italy's antitrust said on Thursday it had fined e-commerce giant Amazon 1.13 billion euros ($1.28 billion) for alleged abuse of market dominance.</p><p><blockquote>意大利反垄断机构周四表示，因涉嫌滥用市场支配地位，已对电子商务巨头亚马逊处以 11.3 亿欧元（12.8 亿美元）的罚款。</blockquote></p><p> In a statement the watchdog said Amazon had harmed competing operators in the e-commerce logistics service.</p><p><blockquote>该监管机构在一份声明中表示，亚马逊损害了电子商务物流服务领域的竞争运营商。</blockquote></p><p> \"Amazon holds a dominant position in the Italian market for intermediation services on marketplaces, which Amazon leveraged to favour the adoption of its own logistics service - Fulfilment by Amazon (FBA) - by sellers active on Amazon.it to the detriment of the logistics services offered by competing operators, as well as to strengthen its own dominant position,\" it added.</p><p><blockquote>“亚马逊在意大利市场中介服务市场上占据主导地位，亚马逊利用这一点来鼓励活跃在亚马逊上的卖家采用自己的物流服务——亚马逊履行（FBA）。这损害了竞争对手提供的物流服务运营商，以及加强自己的主导地位，”它补充道。</blockquote></p><p> The antitrust said it would impose on Amazon corrective steps that will be subject to review by a monitoring trustee.</p><p><blockquote>该反垄断机构表示，将对亚马逊采取纠正措施，并接受监控受托人的审查。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129645066","content_text":"Amazon shares fell slightly by 0.5% in premarket trading after Italy's antitrust fined Amazon 1.13 bln euros for alleged abuse of market dominance.\n\nItaly's antitrust said on Thursday it had fined e-commerce giant Amazon 1.13 billion euros ($1.28 billion) for alleged abuse of market dominance.\nIn a statement the watchdog said Amazon had harmed competing operators in the e-commerce logistics service.\n\"Amazon holds a dominant position in the Italian market for intermediation services on marketplaces, which Amazon leveraged to favour the adoption of its own logistics service - Fulfilment by Amazon (FBA) - by sellers active on Amazon.it to the detriment of the logistics services offered by competing operators, as well as to strengthen its own dominant position,\" it added.\nThe antitrust said it would impose on Amazon corrective steps that will be subject to review by a monitoring trustee.","news_type":1,"symbols_score_info":{"AMZN":0.9}},"isVote":1,"tweetType":1,"viewCount":3491,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699232578,"gmtCreate":1639805865423,"gmtModify":1639805865534,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"title":"","htmlText":"mmmm&nbsp;","listText":"mmmm&nbsp;","text":"mmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699232578","repostId":"1109831591","repostType":4,"repost":{"id":"1109831591","kind":"news","pubTimestamp":1639804463,"share":"https://www.laohunote.com/m/news/1109831591?lang=zh_CN&edition=full","pubTime":"2021-12-18 13:14","market":"us","language":"en","title":"Why Pfizer and Johnson & Johnson Fell on Friday<blockquote>为什么辉瑞和强生公司周五下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1109831591","media":"Motley Fool","summary":"What happened\nTwo prominent U.S. coronavirus stocks ended the week on a down note. Pfizer and Johnso","content":"<p>What happened</p><p><blockquote>发生了什么事</blockquote></p><p> Two prominent U.S. coronavirus stocks ended the week on a down note.&nbsp;<a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>&nbsp;and&nbsp;<a href=\"https://laohu8.com/S/JNJ\"><b>Johnson &amp; Johnson</b></a>&nbsp;both fell on the day by nearly 3%. This followed a prominent investment bank's rather lukewarm take on their current prospects.</p><p><blockquote>两只著名的美国冠状病毒股票本周收盘下跌。<a href=\"https://laohu8.com/S/PFE\"><b>辉瑞</b></a>和<a href=\"https://laohu8.com/S/JNJ\"><b>强生公司</b></a>两者当天均下跌近3%。此前，一家著名投资银行对其当前前景持相当冷淡的态度。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c6a2f152eebbe10f5ab65a99815f461c\" tg-width=\"975\" tg-height=\"637\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> So what</p><p><blockquote>那又怎样</blockquote></p><p> <b>Goldman Sachs</b>&nbsp;analyst Chris Shibutani initiated coverage on Pfizer and Johnson &amp; Johnson on Friday, tagging both high-profile healthcare industry stocks with neutral recommendations.</p><p><blockquote><b>高盛</b>分析师克里斯·涩谷 (Chris Shibutani) 周五开始对辉瑞和强生公司进行报道，对这两只备受瞩目的医疗保健行业股票给予中性建议。</blockquote></p><p> Shibutani is concerned with what he considers to be Pfizer's somewhat cloudy future, despite the great success of the Comirnaty coronavirus vaccine it developed with Germanbiotech&nbsp;<b>BioNTech</b>.</p><p><blockquote>尽管辉瑞与德国生物技术公司合作开发的 Comirnaty 冠状病毒疫苗取得了巨大成功，但涩谷仍对他认为辉瑞有些模糊的未来感到担忧<b>生物技术</b>.</blockquote></p><p> \"Our views on [Pfizer] come down to that we estimate around one-third of its current valuation is attributed to the COVID-19 vaccine and therapeutic [products], and we feel the trajectory for both remains highly uncertain,\" he wrote.</p><p><blockquote>他写道：“我们对辉瑞的看法是，我们估计其当前估值的三分之一左右归因于 COVID-19 疫苗和治疗产品，我们认为两者的发展轨迹仍然高度不确定。”</blockquote></p><p> As for Johnson &amp; Johnson, the prognosticator feels the stock is also fairly valued. However, he sounded a more optimistic note about the company's potential.</p><p><blockquote>至于强生公司，预测者认为该股的估值也相当合理。然而，他对该公司的潜力表示了更乐观的态度。</blockquote></p><p> \"With [Johnson &amp; Johnson] in the midst of transitions across several domains for the organization ... we see possibilities -- even within an organization of [Johnson &amp; Johnson]'s scale and scope -- for additional potentially disruptive opportunities to develop that could reshape the investment thesis, in our view,\" he wrote.</p><p><blockquote>“随着 [强生] 正在组织的多个领域进行转型……我们看到了可能性——即使在 [强生] 规模和范围的组织内——额外的潜在颠覆性发展机会的可能性，我们认为，这可能会重塑投资论点，”他写道。</blockquote></p><p> Last month, Johnson &amp; Johnson announced plans to spin off its sprawlingconsumer healthcare division.</p><p><blockquote>上个月，强生公司宣布计划剥离其庞大的消费者医疗保健部门。</blockquote></p><p> Shibutani's price target on Pfizer stock is $51 per share, and that for Johnson &amp; Johnson is $161.</p><p><blockquote>涩谷对辉瑞股票的目标价为每股 51 美元，强生公司的目标价为每股 161 美元。</blockquote></p><p> Now what</p><p><blockquote>现在呢</blockquote></p><p> Pfizer and Johnson &amp; Johnson are certainly heading into some uncertain waters -- both with the coronavirus and, in the latter company's case, the apparently looming spinoff. To my mind, though, the two companies have plenty of strength in numerous product areas outside of their respective vaccines, so investors shouldn't be too discouraged by Goldman Sachs' latest evaluations.</p><p><blockquote>辉瑞（Pfizer）和强生公司（Johnson &amp; Johnson）无疑正进入一些不确定的水域——无论是冠状病毒，还是后者显然迫在眉睫的分拆。不过，在我看来，两家公司在各自疫苗之外的众多产品领域都拥有足够的实力，因此投资者不应对高盛的最新评估感到太气馁。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Pfizer and Johnson & Johnson Fell on Friday<blockquote>为什么辉瑞和强生公司周五下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Pfizer and Johnson & Johnson Fell on Friday<blockquote>为什么辉瑞和强生公司周五下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-12-18 13:14</span>\n</p>\n</h4>\n</header>\n<article>\n<p>What happened</p><p><blockquote>发生了什么事</blockquote></p><p> Two prominent U.S. coronavirus stocks ended the week on a down note.&nbsp;<a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>&nbsp;and&nbsp;<a href=\"https://laohu8.com/S/JNJ\"><b>Johnson &amp; Johnson</b></a>&nbsp;both fell on the day by nearly 3%. This followed a prominent investment bank's rather lukewarm take on their current prospects.</p><p><blockquote>两只著名的美国冠状病毒股票本周收盘下跌。<a href=\"https://laohu8.com/S/PFE\"><b>辉瑞</b></a>和<a href=\"https://laohu8.com/S/JNJ\"><b>强生公司</b></a>两者当天均下跌近3%。此前，一家著名投资银行对其当前前景持相当冷淡的态度。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c6a2f152eebbe10f5ab65a99815f461c\" tg-width=\"975\" tg-height=\"637\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> So what</p><p><blockquote>那又怎样</blockquote></p><p> <b>Goldman Sachs</b>&nbsp;analyst Chris Shibutani initiated coverage on Pfizer and Johnson &amp; Johnson on Friday, tagging both high-profile healthcare industry stocks with neutral recommendations.</p><p><blockquote><b>高盛</b>分析师克里斯·涩谷 (Chris Shibutani) 周五开始对辉瑞和强生公司进行报道，对这两只备受瞩目的医疗保健行业股票给予中性建议。</blockquote></p><p> Shibutani is concerned with what he considers to be Pfizer's somewhat cloudy future, despite the great success of the Comirnaty coronavirus vaccine it developed with Germanbiotech&nbsp;<b>BioNTech</b>.</p><p><blockquote>尽管辉瑞与德国生物技术公司合作开发的 Comirnaty 冠状病毒疫苗取得了巨大成功，但涩谷仍对他认为辉瑞有些模糊的未来感到担忧<b>生物技术</b>.</blockquote></p><p> \"Our views on [Pfizer] come down to that we estimate around one-third of its current valuation is attributed to the COVID-19 vaccine and therapeutic [products], and we feel the trajectory for both remains highly uncertain,\" he wrote.</p><p><blockquote>他写道：“我们对辉瑞的看法是，我们估计其当前估值的三分之一左右归因于 COVID-19 疫苗和治疗产品，我们认为两者的发展轨迹仍然高度不确定。”</blockquote></p><p> As for Johnson &amp; Johnson, the prognosticator feels the stock is also fairly valued. However, he sounded a more optimistic note about the company's potential.</p><p><blockquote>至于强生公司，预测者认为该股的估值也相当合理。然而，他对该公司的潜力表示了更乐观的态度。</blockquote></p><p> \"With [Johnson &amp; Johnson] in the midst of transitions across several domains for the organization ... we see possibilities -- even within an organization of [Johnson &amp; Johnson]'s scale and scope -- for additional potentially disruptive opportunities to develop that could reshape the investment thesis, in our view,\" he wrote.</p><p><blockquote>“随着 [强生] 正在组织的多个领域进行转型……我们看到了可能性——即使在 [强生] 规模和范围的组织内——额外的潜在颠覆性发展机会的可能性，我们认为，这可能会重塑投资论点，”他写道。</blockquote></p><p> Last month, Johnson &amp; Johnson announced plans to spin off its sprawlingconsumer healthcare division.</p><p><blockquote>上个月，强生公司宣布计划剥离其庞大的消费者医疗保健部门。</blockquote></p><p> Shibutani's price target on Pfizer stock is $51 per share, and that for Johnson &amp; Johnson is $161.</p><p><blockquote>涩谷对辉瑞股票的目标价为每股 51 美元，强生公司的目标价为每股 161 美元。</blockquote></p><p> Now what</p><p><blockquote>现在呢</blockquote></p><p> Pfizer and Johnson &amp; Johnson are certainly heading into some uncertain waters -- both with the coronavirus and, in the latter company's case, the apparently looming spinoff. To my mind, though, the two companies have plenty of strength in numerous product areas outside of their respective vaccines, so investors shouldn't be too discouraged by Goldman Sachs' latest evaluations.</p><p><blockquote>辉瑞（Pfizer）和强生公司（Johnson &amp; Johnson）无疑正进入一些不确定的水域——无论是冠状病毒，还是后者显然迫在眉睫的分拆。不过，在我看来，两家公司在各自疫苗之外的众多产品领域都拥有足够的实力，因此投资者不应对高盛的最新评估感到太气馁。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/12/17/why-pfizer-and-johnson-johnson-fell-on-friday/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/12/17/why-pfizer-and-johnson-johnson-fell-on-friday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109831591","content_text":"What happened\nTwo prominent U.S. coronavirus stocks ended the week on a down note. Pfizer and Johnson & Johnson both fell on the day by nearly 3%. This followed a prominent investment bank's rather lukewarm take on their current prospects.\n\nSo what\nGoldman Sachs analyst Chris Shibutani initiated coverage on Pfizer and Johnson & Johnson on Friday, tagging both high-profile healthcare industry stocks with neutral recommendations.\nShibutani is concerned with what he considers to be Pfizer's somewhat cloudy future, despite the great success of the Comirnaty coronavirus vaccine it developed with Germanbiotech BioNTech.\n\"Our views on [Pfizer] come down to that we estimate around one-third of its current valuation is attributed to the COVID-19 vaccine and therapeutic [products], and we feel the trajectory for both remains highly uncertain,\" he wrote.\nAs for Johnson & Johnson, the prognosticator feels the stock is also fairly valued. However, he sounded a more optimistic note about the company's potential.\n\"With [Johnson & Johnson] in the midst of transitions across several domains for the organization ... we see possibilities -- even within an organization of [Johnson & Johnson]'s scale and scope -- for additional potentially disruptive opportunities to develop that could reshape the investment thesis, in our view,\" he wrote.\nLast month, Johnson & Johnson announced plans to spin off its sprawlingconsumer healthcare division.\nShibutani's price target on Pfizer stock is $51 per share, and that for Johnson & Johnson is $161.\nNow what\nPfizer and Johnson & Johnson are certainly heading into some uncertain waters -- both with the coronavirus and, in the latter company's case, the apparently looming spinoff. To my mind, though, the two companies have plenty of strength in numerous product areas outside of their respective vaccines, so investors shouldn't be too discouraged by Goldman Sachs' latest evaluations.","news_type":1,"symbols_score_info":{"PFE":0.9,"JNJ":0.9}},"isVote":1,"tweetType":1,"viewCount":3122,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600550505,"gmtCreate":1638177679665,"gmtModify":1638177748090,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"title":"","htmlText":"[财迷]&nbsp;","listText":"[财迷]&nbsp;","text":"[财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600550505","repostId":"1106015985","repostType":2,"repost":{"id":"1106015985","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638176514,"share":"https://www.laohunote.com/m/news/1106015985?lang=zh_CN&edition=full","pubTime":"2021-11-29 17:01","market":"us","language":"en","title":"Moderna stock surged 8% in premarket trading<blockquote>Moderna 股价在盘前交易中飙升 8%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1106015985","media":"Tiger Newspress","summary":"Moderna stock surged 8% in premarket trading as it said new covid-19 vaccine for Omicron might be re","content":"<p>Moderna stock surged 8% in premarket trading&nbsp;as&nbsp;it&nbsp;said new covid-19 vaccine for Omicron might be ready in early 2022.</p><p><blockquote>Moderna 股价在盘前交易中飙升 8%，因为该公司表示奥密克戎的新型 covid-19 疫苗可能会在 2022 年初准备就绪。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/660e8ece7a2b338498e4bfe9f3c38228\" tg-width=\"851\" tg-height=\"616\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Moderna&nbsp;chief medical officer Paul Burton said he suspects the new Omicron coronavirus variant may elude current vaccines, and if so, a reformulated shot could be available early in the new year.</p><p><blockquote>Moderna首席医疗官Paul Burton表示，他怀疑新的奥密克戎冠状病毒变种可能会躲过当前的疫苗，如果是这样，重新配制的疫苗可能会在新年伊始上市。</blockquote></p><p> \"We should know about the ability of the current vaccine to provide protection in the next couple of weeks,\" Mr Burton said on Sunday (Nov 28) on the BBC's Andrew Marr Show.</p><p><blockquote>伯顿周日（11 月 28 日）在 BBC 安德鲁·马尔秀节目中表示：“我们应该了解当前疫苗在未来几周内提供保护的能力。”</blockquote></p><p> \"If we have to make a brand new vaccine, I think that's going to be early 2022 before that's really going to be available in large quantities,\" he said.</p><p><blockquote>“如果我们必须制造一种全新的疫苗，我认为要到 2022 年初才能真正大量上市，”他说。</blockquote></p><p> \"The remarkable thing about the mRNA vaccines, the Moderna platform, is that we can move very fast,\" he added.</p><p><blockquote>“mRNA 疫苗（Moderna 平台）的非凡之处在于我们可以非常快速地移动，”他补充道。</blockquote></p><p> The Cambridge, Massachusetts-based biotech company mobilised \"hundreds\" of staff early last&nbsp;Thursday, Thanksgiving Day in the United States, after news of the Omicron variant spread.</p><p><blockquote>上周四美国感恩节早些时候，在奥密克戎变种病毒的消息传开后，这家总部位于马萨诸塞州剑桥的生物技术公司动员了“数百名”员工。</blockquote></p><p> Protection should still exist, depending on how long ago a person was vaccinated, and for now the best advice is to take one of the current Covid-19 vaccines, Mr Burton said.</p><p><blockquote>伯顿先生说，保护应该仍然存在，这取决于一个人接种疫苗的时间，目前最好的建议是接种当前的 Covid-19 疫苗之一。</blockquote></p><p> \"If people are on the fence, and you haven't been vaccinated, get vaccinated,\" he said. \"This is a dangerous-looking virus, but I think we have many tools in our armamentarium now to fight it.\"</p><p><blockquote>“如果人们持观望态度，而你还没有接种疫苗，那就接种疫苗，”他说。“这是一种看起来很危险的病毒，但我认为我们现在的武器库中有很多工具可以对抗它。”</blockquote></p><p> The emergence of the Omicron strain has seen countries rush to clamp down on travel from southern Africa.</p><p><blockquote>奥密克戎病毒的出现导致各国急于限制来自南部非洲的旅行。</blockquote></p><p> Fears that it could exacerbate a winter Covid-19 surge in the northern hemisphere and undermine a global economic recovery sent a wave of risk aversion across global markets last&nbsp;Friday that continued on Sunday when the Middle East opened for the week.</p><p><blockquote>上周五，由于担心这可能会加剧北半球冬季新冠肺炎疫情激增并破坏全球经济复苏，全球市场掀起了一波避险情绪，这种情绪在周日中东开盘时仍在继续。</blockquote></p><p> Moderna said in a release on Friday that it was working rapidly to test the current vaccine against the Omicron variant, and studying two booster candidates.</p><p><blockquote>Moderna在周五的一份新闻稿中表示，它正在快速测试当前针对奥密克戎变种的疫苗，并研究两种候选加强剂。</blockquote></p><p> \"Since early 2021, Moderna has advanced a comprehensive strategy to anticipate new variants of concern,\" the company said. \"The company has repeatedly demonstrated the ability to advance new candidates to clinical testing in 60 to 90 days.\"</p><p><blockquote>该公司表示：“自 2021 年初以来，Moderna 已推进一项全面战略，以预测令人担忧的新变种。”“该公司已多次证明有能力在 60 至 90 天内将新候选药物推进临床试验。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock surged 8% in premarket trading<blockquote>Moderna 股价在盘前交易中飙升 8%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock surged 8% in premarket trading<blockquote>Moderna 股价在盘前交易中飙升 8%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 17:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Moderna stock surged 8% in premarket trading&nbsp;as&nbsp;it&nbsp;said new covid-19 vaccine for Omicron might be ready in early 2022.</p><p><blockquote>Moderna 股价在盘前交易中飙升 8%，因为该公司表示奥密克戎的新型 covid-19 疫苗可能会在 2022 年初准备就绪。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/660e8ece7a2b338498e4bfe9f3c38228\" tg-width=\"851\" tg-height=\"616\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Moderna&nbsp;chief medical officer Paul Burton said he suspects the new Omicron coronavirus variant may elude current vaccines, and if so, a reformulated shot could be available early in the new year.</p><p><blockquote>Moderna首席医疗官Paul Burton表示，他怀疑新的奥密克戎冠状病毒变种可能会躲过当前的疫苗，如果是这样，重新配制的疫苗可能会在新年伊始上市。</blockquote></p><p> \"We should know about the ability of the current vaccine to provide protection in the next couple of weeks,\" Mr Burton said on Sunday (Nov 28) on the BBC's Andrew Marr Show.</p><p><blockquote>伯顿周日（11 月 28 日）在 BBC 安德鲁·马尔秀节目中表示：“我们应该了解当前疫苗在未来几周内提供保护的能力。”</blockquote></p><p> \"If we have to make a brand new vaccine, I think that's going to be early 2022 before that's really going to be available in large quantities,\" he said.</p><p><blockquote>“如果我们必须制造一种全新的疫苗，我认为要到 2022 年初才能真正大量上市，”他说。</blockquote></p><p> \"The remarkable thing about the mRNA vaccines, the Moderna platform, is that we can move very fast,\" he added.</p><p><blockquote>“mRNA 疫苗（Moderna 平台）的非凡之处在于我们可以非常快速地移动，”他补充道。</blockquote></p><p> The Cambridge, Massachusetts-based biotech company mobilised \"hundreds\" of staff early last&nbsp;Thursday, Thanksgiving Day in the United States, after news of the Omicron variant spread.</p><p><blockquote>上周四美国感恩节早些时候，在奥密克戎变种病毒的消息传开后，这家总部位于马萨诸塞州剑桥的生物技术公司动员了“数百名”员工。</blockquote></p><p> Protection should still exist, depending on how long ago a person was vaccinated, and for now the best advice is to take one of the current Covid-19 vaccines, Mr Burton said.</p><p><blockquote>伯顿先生说，保护应该仍然存在，这取决于一个人接种疫苗的时间，目前最好的建议是接种当前的 Covid-19 疫苗之一。</blockquote></p><p> \"If people are on the fence, and you haven't been vaccinated, get vaccinated,\" he said. \"This is a dangerous-looking virus, but I think we have many tools in our armamentarium now to fight it.\"</p><p><blockquote>“如果人们持观望态度，而你还没有接种疫苗，那就接种疫苗，”他说。“这是一种看起来很危险的病毒，但我认为我们现在的武器库中有很多工具可以对抗它。”</blockquote></p><p> The emergence of the Omicron strain has seen countries rush to clamp down on travel from southern Africa.</p><p><blockquote>奥密克戎病毒的出现导致各国急于限制来自南部非洲的旅行。</blockquote></p><p> Fears that it could exacerbate a winter Covid-19 surge in the northern hemisphere and undermine a global economic recovery sent a wave of risk aversion across global markets last&nbsp;Friday that continued on Sunday when the Middle East opened for the week.</p><p><blockquote>上周五，由于担心这可能会加剧北半球冬季新冠肺炎疫情激增并破坏全球经济复苏，全球市场掀起了一波避险情绪，这种情绪在周日中东开盘时仍在继续。</blockquote></p><p> Moderna said in a release on Friday that it was working rapidly to test the current vaccine against the Omicron variant, and studying two booster candidates.</p><p><blockquote>Moderna在周五的一份新闻稿中表示，它正在快速测试当前针对奥密克戎变种的疫苗，并研究两种候选加强剂。</blockquote></p><p> \"Since early 2021, Moderna has advanced a comprehensive strategy to anticipate new variants of concern,\" the company said. \"The company has repeatedly demonstrated the ability to advance new candidates to clinical testing in 60 to 90 days.\"</p><p><blockquote>该公司表示：“自 2021 年初以来，Moderna 已推进一项全面战略，以预测令人担忧的新变种。”“该公司已多次证明有能力在 60 至 90 天内将新候选药物推进临床试验。”</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106015985","content_text":"Moderna stock surged 8% in premarket trading as it said new covid-19 vaccine for Omicron might be ready in early 2022.\n\nModerna chief medical officer Paul Burton said he suspects the new Omicron coronavirus variant may elude current vaccines, and if so, a reformulated shot could be available early in the new year.\n\"We should know about the ability of the current vaccine to provide protection in the next couple of weeks,\" Mr Burton said on Sunday (Nov 28) on the BBC's Andrew Marr Show.\n\"If we have to make a brand new vaccine, I think that's going to be early 2022 before that's really going to be available in large quantities,\" he said.\n\"The remarkable thing about the mRNA vaccines, the Moderna platform, is that we can move very fast,\" he added.\nThe Cambridge, Massachusetts-based biotech company mobilised \"hundreds\" of staff early last Thursday, Thanksgiving Day in the United States, after news of the Omicron variant spread.\nProtection should still exist, depending on how long ago a person was vaccinated, and for now the best advice is to take one of the current Covid-19 vaccines, Mr Burton said.\n\"If people are on the fence, and you haven't been vaccinated, get vaccinated,\" he said. \"This is a dangerous-looking virus, but I think we have many tools in our armamentarium now to fight it.\"\nThe emergence of the Omicron strain has seen countries rush to clamp down on travel from southern Africa.\nFears that it could exacerbate a winter Covid-19 surge in the northern hemisphere and undermine a global economic recovery sent a wave of risk aversion across global markets last Friday that continued on Sunday when the Middle East opened for the week.\nModerna said in a release on Friday that it was working rapidly to test the current vaccine against the Omicron variant, and studying two booster candidates.\n\"Since early 2021, Moderna has advanced a comprehensive strategy to anticipate new variants of concern,\" the company said. \"The company has repeatedly demonstrated the ability to advance new candidates to clinical testing in 60 to 90 days.\"","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1164,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699238053,"gmtCreate":1639805119710,"gmtModify":1639805119710,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"title":"","htmlText":"buy at dip?&nbsp;[Cool]&nbsp;","listText":"buy at dip?&nbsp;[Cool]&nbsp;","text":"buy at dip? [Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699238053","repostId":"1113352768","repostType":4,"repost":{"id":"1113352768","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639752492,"share":"https://www.laohunote.com/m/news/1113352768?lang=zh_CN&edition=full","pubTime":"2021-12-17 22:48","market":"us","language":"en","title":"Amazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group<blockquote>印度暂停与 Future Group 2019 年的交易，亚马逊早盘下跌近 2%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1113352768","media":"Tiger Newspress","summary":"Amazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group.India's ","content":"<p>Amazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group.<img src=\"https://static.tigerbbs.com/ecaa54686b8d8b0541b8769a2aa237a3\" tg-width=\"766\" tg-height=\"567\" width=\"100%\" height=\"auto\">India's antitrust body on Friday suspended Amazon.com's 2019 deal with Future Group following a review of allegations that the U.S. e-commerce giant had concealed information while seeking regulatory approval.</p><p><blockquote>由于印度暂停了与 Future Group 2019 年的交易，亚马逊在早盘交易中下跌近 2%。印度反垄断机构周五暂停了亚马逊 2019 年与 Future Group 的交易，此前该机构审查了有关这家美国电子商务巨头在寻求监管部门批准时隐瞒信息的指控。</blockquote></p><p> The unprecedented step taken by the Competition Commission of India (CCI) could have far-reaching consequences on Amazon's legal battles with now estranged partner Future. The U.S. firm has for months successfully used the terms of its toehold $200 million investment in 2019 to block Future's attempt to sell retail assets to Reliance Industries for $3.4 billion.</p><p><blockquote>印度竞争委员会（CCI）采取的史无前例的举措可能会对亚马逊与现已疏远的合作伙伴Future的法律诉讼产生深远的影响。几个月来，这家美国公司成功地利用其 2019 年 2 亿美元投资的条款，阻止 Future 以 34 亿美元的价格向 Reliance Industries 出售零售资产的企图。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group<blockquote>印度暂停与 Future Group 2019 年的交易，亚马逊早盘下跌近 2%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group<blockquote>印度暂停与 Future Group 2019 年的交易，亚马逊早盘下跌近 2%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-17 22:48</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Amazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group.<img src=\"https://static.tigerbbs.com/ecaa54686b8d8b0541b8769a2aa237a3\" tg-width=\"766\" tg-height=\"567\" width=\"100%\" height=\"auto\">India's antitrust body on Friday suspended Amazon.com's 2019 deal with Future Group following a review of allegations that the U.S. e-commerce giant had concealed information while seeking regulatory approval.</p><p><blockquote>由于印度暂停了与 Future Group 2019 年的交易，亚马逊在早盘交易中下跌近 2%。印度反垄断机构周五暂停了亚马逊 2019 年与 Future Group 的交易，此前该机构审查了有关这家美国电子商务巨头在寻求监管部门批准时隐瞒信息的指控。</blockquote></p><p> The unprecedented step taken by the Competition Commission of India (CCI) could have far-reaching consequences on Amazon's legal battles with now estranged partner Future. The U.S. firm has for months successfully used the terms of its toehold $200 million investment in 2019 to block Future's attempt to sell retail assets to Reliance Industries for $3.4 billion.</p><p><blockquote>印度竞争委员会（CCI）采取的史无前例的举措可能会对亚马逊与现已疏远的合作伙伴Future的法律诉讼产生深远的影响。几个月来，这家美国公司成功地利用其 2019 年 2 亿美元投资的条款，阻止 Future 以 34 亿美元的价格向 Reliance Industries 出售零售资产的企图。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113352768","content_text":"Amazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group.India's antitrust body on Friday suspended Amazon.com's 2019 deal with Future Group following a review of allegations that the U.S. e-commerce giant had concealed information while seeking regulatory approval.\nThe unprecedented step taken by the Competition Commission of India (CCI) could have far-reaching consequences on Amazon's legal battles with now estranged partner Future. The U.S. firm has for months successfully used the terms of its toehold $200 million investment in 2019 to block Future's attempt to sell retail assets to Reliance Industries for $3.4 billion.","news_type":1,"symbols_score_info":{"AMZN":0.9}},"isVote":1,"tweetType":1,"viewCount":3434,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}